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ABSTRACT

TRANSCRIPTION REGULATION OF HUMAN IL1B GENE IN MONOCYTES AND
LYMPHOID CD4 T CELLS

By
Sree H. Pulugulla
December 2019

Dissertation supervised by Dr. Philip E. Auron.
Cytokines are key regulators of the inflammatory response and play an important role in
facilitating intercellular communication between various immune cell types. Interleukin-1b (IL-1b)
is a potent pro-inflammatory cytokine that is required for robust initiation of innate immune
response and subsequent development of adaptive immunity. IL-1b is first synthesized as an
inactive cytoplasmic, non-glycosylated, precursor molecule (proIL-1b) by monocytes and
macrophages in response to invading pathogenic microbes. The activation of caspase-1 by
inflammasomes cleaves proIL-1b into mature biologically active IL-1b that is released from cells
via a non-classical, endoplasmic reticulum-independent secretory pathway directly from the
cytoplasm via Gasdermin D membrane pores. IL-1b binds to its heterodimeric receptor
(IL-1R1•IL1RAP) on various immune cells, resulting in an inflammatory response that in short
transient bursts can be therapeutic. However, increased and sustained expression of IL-1b is known
to be associated with many autoinflammatory diseases. Therefore, understanding the molecular
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mechanisms regulating human IL1B gene transcription is important for discovering potential
regulatory control points in this immunologically important gene, as well as for designing more
effective and safer anti-IL-1b therapies than those currently available. Most of our present
understanding of IL1B gene regulation is from activated monocytes, but not much is known about
its regulation in lymphoid CD4 T cells. Previous studies from our lab have shown that the Spi1/PU.1 (Spi1) transcription factor is absolutely necessary for IL1B gene transcription in monocytes.
Using mRNA expression and Chromatin Immunoprecipitation (ChIP), we have shown that the
IL1B gene in TCR-activated CD4 T cells is transcribed from a low-activity bivalent
H3K4me3+/H3K27me3+ promoter in a Spi1-independent manner. Our lab has previously reported
that IL1B gene transcription is dependent upon long-range chromatin looping mediated by a mutual
DNA-binding domain interaction between two transcription factors, Spi1 at the promoter and
C/EBPb at a distal enhancer. Using in vitro interaction and computational analysis, we have
generated a predicted molecular structure of the C/EBPb:Spi1 protein-protein interaction and
demonstrated that C-terminal tail residues beyond the C/EBPb leucine zipper are critical for
mediating its interaction with the DNA-binding domain of Spi1. We have also reported that a small
molecule can effectively bind to a pocket on Spi1 disrupting its interaction with C/EBPb, thereby
significantly reducing IL1B gene transcription in TLR4-activated THP-1 monocytes. Using
mRNA kinetic expression profiling, relatively-specific transcription factor inhibition and ChIP,
we have identified a differential involvement of NF-κB and C/EBPβ transcription factors in
TLR4-dependent IL1B gene transcription in monocytes. We have also demonstrated that serine
phosphorylation of Spi1 plays an important role in facilitating IL1B gene expression.
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Chapter 1: Introduction
1.1. Overview of the Immune System
Our human bodies are constantly exposed to a wide range of microorganisms from the
environment. The majority of these microorganisms are not harmful and peacefully coexist within
the host. However, some of the microorganisms are pathogenic and can lead to a number of
life-threatening conditions. The constant interplay between the host and these foreign agents has
led to the development of a complex immune system to protect the host from these invading
pathogenic microbes. The immune system is composed of a complex interactive network of cells,
tissues, organs, humoral factors and cytokines that protects the host against the invading foreign
pathogens. The primary function of the immune system is to discriminate “self” antigens from
“non-self” antigens. This ability of the immune system, to avoid the destruction of the host’s own
cells and tissues is referred to as self-tolerance (Chaplin, 2010). The failure of self-tolerance can
lead to a broad range of autoimmune diseases where the host’s immune system attacks and destroys
its own cells and tissues. The immune system is broadly divided into two distinct groups based on
the speed and specificity of the response: innate immunity and adaptive immunity.
The innate immune system serves as the first line of host defense against invading
pathogens and other foreign agents. The innate immune response occurs rapidly upon exposure to
pathogens and relies on the recognition of conserved molecular structures among a wide array of
pathogens (Janeway and Medzhitov, 2002). It provides “non-specific” destruction of pathogens
and does not lead to the formation of long-lasting immunologic memory. It also plays a crucial
part in the initiation of an adaptive immune response.
In contrast to innate immunity, the adaptive immune response is highly specific to a
particular pathogen and takes longer to develop. In addition to pathogen specificity, a key feature
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of adaptive immunity is the generation of long-lasting immunologic memory which ensures a more
rapid and effective response against a specific pathogen during its second encounter (Bonilla and
Oettgen, 2010). This feature of adaptive immunity forms the basis of vaccination and provides
lasting protective immunity. The two main cell types of the adaptive immune system are T
lymphocytes and B lymphocytes. The receptor on individual lymphocytes is highly specific and
distinct as a result of random somatic gene rearrangement during their maturation. The clonal
expansion nature of lymphocytes is a hallmark of the adaptive immune response. When a specific
antigen binds to a receptor on a naïve lymphocyte, that particular cell gets activated and starts to
clonally expand. This gives rise to a clone of identical lymphocytes bearing the same antigen
receptor (Heinzel et al., 2018).

1.2. Innate Immune System: Cells and Pattern Recognition
The innate immune system as the first line of defense consists of a series of anatomical,
physiological and chemical barriers to prevent the foreign pathogens from entering the host. These
barriers include: epithelial cell layers that express tight cell-cell contacts (intact skin); secreted
mucus that traps infectious pathogens; epithelial cilia that clears the mucus and other trapped
particles; and low stomach pH and bacteriolytic enzymes like lysozyme in tears, saliva and other
secretions (Chaplin, 2010; Turvey and Broide, 2010). Once an infectious pathogen penetrates these
physical and chemical barriers, the cellular and humoral components of the innate immune
response are triggered to effectively remove the invading foreign pathogen.
Immune cells develop from the pluripotent hematopoietic stem cells in the bone marrow.
These stem cells can differentiate into either common myeloid or common lymphoid progenitor
cells. Myeloid progenitor cells are the precursor to several prominent innate immune cells
including macrophages, dendritic cells, granulocytes and mast cells (Chaplin, 2010). Macrophages
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are highly phagocytic cells that engulf microbes and other foreign particles that are marked for
clearance by immunoglobins (Ig) or the complement system. During inflammation, monocytes
circulating in the blood differentiate into macrophages and migrate into the tissues to fight
infection. Both monocytes and macrophages have a broad range of pattern recognition receptors
which, upon encountering microbes, initiates a cascade of downstream signaling events that result
in the expression of many pro-inflammatory genes. Macrophages are broadly classified into M1
macrophages (classically activated) and M2 macrophages (alternatively activated). M1
macrophages are activated by Toll-like receptor ligands such as Lipopolysaccharides (LPS) or type
2 interferon (IFN-g) and express pro-inflammatory cytokines. M1 macrophages play an important
role in host defense against bacteria, protozoa, viruses and also aid in antitumor immunity (Murray
and Wynn, 2011). M2 macrophages are generally stimulated by interleukin-4 (IL-4) or IL-13. M2
macrophages have an anti-inflammatory function and play a role in wound healing and tissue
repair (Italiani and Boraschi, 2014). Dendritic cells (DC) are specialized antigen presenting cells
(APC) that phagocytize antigen and present it to lymphocytes. When an immature DC encounters
a pathogen, it rapidly matures and migrates to lymph nodes where lymphocytes reside. DCs act as
a bridge between innate and adaptive immune systems. Unlike classical DCs, plasmacytoid DCs
are relatively long-lived and respond to viral infection by secreting large quantities of type 1 IFN
(Geissmann et al., 2010).
Mast cells generally reside in connective tissue and mucous membrane, and when activated,
release a number of chemical mediators like histamine that causes increased blood flow and cell
trafficking to the area of infection. These cells play an important role in allergic responses and
wound healing (Oskeritzian, 2012). Granulocytes include neutrophils, eosinophils, and basophils
are characterized by the presence of dense secretory granules in the cytoplasm. All three types of
granulocytes are generally short-lived. Neutrophils are phagocytic cells that play a major role in
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microbial clearance and tissue repair. They accumulate at sites of bacterial infection and produce
large quantities of reactive oxygen species that are cytotoxic to microbial pathogens (Winterbourn
et al., 2016). Basophils are key initiators of immediate hypersensitivity, allergic immune responses
and immunity against parasitic infections. These cells release substantial amounts of histamine and
IL-4 in response to infection. Eosinophils are very similar to basophils and provide host response
against helminths and other multicellular parasites (Stone et al., 2010). Unlike above mentioned
innate immune cells, Natural Killer (NK) cells are derived from differentiation of common
lymphoid progenitor cells, which also give rise to T lymphocytes and B lymphocytes of the
adaptive immune system. NK cells do not have any antigen-specific receptors. Instead, they have
cell surface receptors for Major Histocompatibility Complex (MHC) class I molecules. The
cytotoxic activity of NK cells is inhibited when they interact with MHC class I molecules on the
host cell. Normal host cells are MHC class I positive and escape from the lytic activity of NK cells.
Tumor cells and virus-infected host cells generally downregulate MHC class I molecule expression
and are targeted by NK cells for killing. NK cells also express Fc receptors and can mediate
antibody dependent cell-mediated cytotoxicity (Caligiuri, 2008).
The cellular component of the innate immune response is dependent upon a limitedrepertoire of germline-encoded pattern recognition receptors (PRRs), which has the ability to
detect conserved molecular structures that are shared by a large variety of microorganisms. These
microbe-derived structures are known as pathogen-associated molecular patterns (PAMPs)
(Matzinger, 1994; Medzhitov and Janeway, 1997). PAMPs are distinct from host self-antigens and
are required for microbial survival. Mutations in these structures are generally lethal for microbes
and are conserved among large groups of pathogens (Medzhitov and Janeway, 1997). PAMPs
include bacterial components such as LPS, peptidoglycan, lipoteichoic acid, and unmethylated
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CpG motifs DNA, as well as fungal molecules like b-glycans and viral glycoproteins and nucleic
acids (Mogensen, 2009).
In addition to PAMPs, the innate immune system, via PRRs, can also recognize a wide
variety of host nuclear and cytosolic products that are released from the stressed cells undergoing
necrosis or tissue damage. These secondary endogenous signals are known as damage-associated
molecular patterns (DAMPs) (Venereau et al., 2015). Well-characterized DAMPs include high
mobility group box 1 protein, heat-shock proteins, uric acid, S100 proteins, defensins, host nucleic
acid and ATP, which under normal physiological conditions are not exposed to PRRs on the
immune cells. Additionally, DAMPs also include a number of extracellular matrix components
such as biglycan, fibronectin, heparan sulfate, hyaluronan and fibrinogen (Roh and Sohn, 2018).
DAMPs have been shown to be associated with a number of human diseases such as: autoimmune
(rheumatoid arthritis); cardiovascular (atherosclerosis); metabolic (type 2 diabetes mellitus) and
neurodegenerative (Parkinson’s) diseases (Foell et al., 2007; Frostegard, 2013; Land, 2015; Shin
et al., 2015).
PRRs are the hallmark of the innate immune response and are absolutely necessary for the
proper functioning of the immune system. There are four major families of PRRs: Toll-like
receptors (TLRs); C-type lectin receptors (CLRs); Retinoic acid-includible gene (RIG)-I-like
receptors (RLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs)
(Takeuchi and Akira, 2010). TLRs and CLRs are transmembrane proteins that are present on the
cell surface, where RLRs and NLRs are cytoplasmic proteins that act as intercellular sensors of
PAMPs and DAMPs.
TLRs are evolutionarily conserved type 1 transmembrane proteins that are homologs of the
Drosophila Toll protein. The extracellular domain of TLRs contains leucine rich repeats (LRRs),
which are involved in ligand binding and mediate PAMP recognition. The cytoplasmic tail region
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contains a highly conserved Toll/IL-1 receptor (TIR) domain that initiates downstream signal
transduction upon receptor activation (Armant and Fenton, 2002). TLRs dimerize upon ligand
binding and initiate downstream signaling cascades through recruitment of adapter proteins like
Myeloid

Differentiation

primary

response

88

(MyD88)

or

TIR-domain-containing

adapter-inducing interferon-b (TRIF) via their cytoplasmic TIR domain. These signaling cascades
ultimately lead to activation of various transcription factors like nuclear factor kappa B (NF-kB),
activator protein-1 (AP-1), interferon-regulatory factor (IRF)-3, which translocate into the nucleus
and induce expression of a number of pro-inflammatory genes. The TLR superfamily is comprises
of 10 genes (TLR1-TLR10) in humans and 12 genes (TLR1-TLR9, TLR11-TLR13), with TLR10
homolog being a pseudogene, in mice (Beutler, 2004). The pattern recognition repertoire of TLRs
is expanded by its ability to form heterodimers with one another. For example, TLR2/TLR6
heterodimers are required for recognizing diacylated lipoproteins whereas TLR1/TLR2
heterodimers interact with triacylated lipoproteins on the bacterial cell wall (Ozinsky et al., 2000).
TLRs are broadly subdivided into two groups based on their localization: cell surface TLRs
and intracellular TLRs. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are expressed on cell
surfaces, whereas intracellular TLR subfamily comprises TLR3, TLR7, TLR8 and TLR9
(Kawasaki and Kawai, 2014). Each TLR family member can recognize a distinct but limited
repertoire of conserved microbial molecules. Microbial membrane components such as lipids,
lipoproteins, and proteins are predominantly recognized by cell surface TLRs. TLR2 along with
either TLR1 or TLR6 can recognize a variety of PAMPs from the cell surface of Gram-positive
bacteria (Kawai and Akira, 2010). TLR4 is mainly activated by LPS, whereas TLR5 recognizes
bacterial flagellin (Akira et al., 2006). Intracellular TLRs generally recognize bacterial and viral
nucleic acids as well as host-nucleic acids in some disease conditions (Blasius and Beutler, 2010).
TLR3 largely responds to double-stranded viral RNA, whereas TLR7 and TLR8 are responsible

6

for the detection of single-stranded viral RNA (Kawasaki and Kawai, 2014). Finally, TLR9 is
implicated in detecting unmethylated CpG bacterial and viral DNA (Kumagai et al., 2008).
CLRs are a part of a large transmembrane receptor superfamily that is responsible for
recognizing carbohydrates on microorganisms such as viruses, bacteria, and fungi (Hoving et al.,
2014). These receptors are generally calcium-dependent and contain at least one carbohydratebinding domain. CLRs initiate intracellular signaling either via their dual-tyrosine ITAM
(Immunoreceptor tyrosine-based activation motif) or adaptor proteins containing ITAM domains
such as fragment crystallizable (Fc) receptor g chain or DAP12 (Geijtenbeek and Gringhuis, 2009).
RLRs are a family of cytosolic receptors that recognize viral RNA and activate type I interferons
and NF-kB dependent pro-inflammatory cytokines. These receptors contain the N-terminal
caspase recruitment domain (CARD) that mediate downstream signaling, a central DEAD box
helicase/ATPase domain that binds viral RNA and a regulatory C-terminal domain (Loo and Gale,
2011). RNA viruses are generally recognized by a specific member of the RLRs family based on
viral RNA length (Kato et al., 2008).
NLRs are intracellular sensors that can sense microbial invasion and cellular stress through
the recognition of cytosolic PAMPs and DAMPs. NLRs are characterized by an N-terminal
effector domain such as CARD, a central nucleotide-binding oligomerization domain (NOD) that
is critical for activation and a C-terminal LRR domain that detects conserved molecular patterns.
There are 23 NLR family members in humans that are classified by their N-terminal effector
domain (Kanneganti et al., 2007). NLRs play an important role in the cytoplasmic/non-membrane
processing of precursor pro-IL1b and pro-IL18. NALP3, one of the NLR proteins containing pyrin
domain 3, can sense metabolic and cellular ‘danger signals’ such as potassium efflux and
extracellular Adenosine triphosphate (ATP) that are released from dying cells due to infection or
sterile inflammation. These metabolic stressors can activate NALP3 leading to its association with
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the adaptor protein apoptosis-associated speck-like protein containing CARD (ASC). The
NALP3:ASC complex through the CARD domain of ASC protein recruits pro-caspase-1 leading
to the formation of an active inflammasome complex (Abderrazak et al., 2015; Latz et al., 2013).
The active inflammasome leads to autocatalytic cleavage of pro-caspase-1 into active caspase-1
which will then cleave pro-IL1b and pro-IL18 into their mature biological active forms. These
biological active cytokines are important mediators of the inflammatory response and are released
from the cells via a non-classical secretion pathway (Dinarello, 2009).

1.3. Human Interleukin-1 Beta Gene
Interleukin 1b (IL-1b) is a key mediator of inflammation and innate immunity. It plays a
crucial role in host-defense response to infection and injury stimuli. It is encoded by the IL1B gene
located on human chromosome 2 (Webb et al., 1986) within an IL1B super-family gene cluster at
band 2q13. There are 11 members in the IL1B gene super-family (9 members at band 2q13 and
one each at 9p24.1 and 11q23.1), of which seven are associated with pro-inflammatory and four
with anti-inflammatory responses (Dinarello, 2018). TLR-activated monocytes/macrophages, as
well as related myeloid lineage cells, act as the primary source of IL-1b in humans. Apart from
being an important mediator of the inflammatory response, IL-1b is involved in a variety of cellular
functions such as cell proliferation, cell maturation, and apoptosis. But the increased and sustained
expression of IL-1b is associated with many auto-inflammatory diseases such as sepsis, osteo- and
rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, gout and asthma (Braddock
and Quinn, 2004). Every year, severe sepsis, alone, affects more than a million people in the United
States (Hall et al., 2011). It is estimated that about 28 to 50 percent of these people die, which is
far more than the deaths from AIDS, prostate cancer and breast cancer combined (Wood and Angus,
2004). Apart from these diseases, IL-1b is also known to play a role in atherosclerosis, stroke,
8

chronic obstructive pulmonary disease, cancer, multiple sclerosis, Alzheimer’s disease and
diabetes (Braddock and Quinn, 2004).
IL1B is an immediate-early (IE) gene with a rapid increase in mRNA levels within 15
minutes after the LPS dependent TLR4-activation of monocytes (Dinarello, 2018). IL1B gene
transcription has two distinct phases with an IE rapid-vigorous phase followed by a decreased
continuous expression that lasts for several hours (Adamik et al., 2013). Unlike other classic IE
genes, like TNF and FOS, IL1B lacks many canonical core promoter elements such as Initiator
(Inr), Downstream Promoter Element (DPE) and Downstream Core Element (DCE) sequences,
which are specifically recognized by protein components of the transcription Pre-Initiation
Complex (PIC) (Nogales et al., 2017). The absence of these sequence elements may be the reason
why the IL1B gene promoter does not have pre-bound TATA-Binding Protein (TBP) and RNA
Polymerase II (Pol II), but instead has the Spi-1/PU.1 (Spi1) transcription factor pre-bound to the
promoter region before TLR-4 activation (Adamik et al., 2013). Spi1 is a monocytic cell lineagedetermining factor that belongs to the ETS family of transcription factors and is absolutely required
for IL1B gene transcription in monocytes (Adamik et al., 2013). Spi1 constitutively binds to the
IL1B promoter between -50 to -39 and may also bind to a site at -115 to -97, relative to the
transcription start site (TSS) (Kominato et al., 1995). The inducible regulatory region of the IL1B
gene is multi-partite, consisting of a short 14 base pair (bp) signal-dependent mini-enhancer
located approximately 300 bp upstream of the TSS, which binds the NF-kB transcription factor
upon TLR-4 activation (Figure 1). In addition, the IL1B gene also has a 400 bp-long far-upstream
super enhancer (UIS: Upstream Induction Sequence) that is essential for a high level of IL1B
transcription in LPS-activated monocytes (Gray et al., 1993; Shirakawa et al., 1993). This
super-enhancer located approximately 3 Kbp upstream of the TSS and binds various constitutively
expressed and TLR4-activated transcription factors (Tsukada et al., 1994; Unlu et al., 2007). Of
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all the transcription factors that can bind to this upstream region, the majority of the LPS-dependent
activity is contributed by the co-operative effect of a 9 bp C/EBPb-dependent heterodimer binding
sequence (Tsukada et al., 1994) and a 21 bp IRF8 dependent heterotrimeric sequence (LILRE:
LPS/IL1B response element) (Unlu et al., 2007). Previous studies have reported that by long-range
LPS-dependent chromatin looping the DNA binding domain (DBD) of C/EBPb (bound to the UIS
enhancer) can directly interact with the Spi1 DBD (located at promoter) (Adamik et al., 2013;
Listman et al., 2005; Tsukada et al., 1994; Yang et al., 2000). These complex transcription factors
interactions and their binding to different regulatory regions along the gene results in the tight
regulation of the IL1B gene.

Figure 1. Regulatory regions of IL1B. Schematic of IL1B gene structure showing the relative
locations of important transcription factor binding sites. Key transcription factor binding sites are
indicated. These include: the -300 NF-kB site; Region I binding site for the critical C/EBPb dimer;
LILRE site for an IRF8:Spi1:Stat1 ternary complex; and two Spi1 sites at the IL1B promoter. This
figure is courtesy of Dr. Philip E. Auron.
IL-1b is first translated into a 31-kDa precursor protein with very low biological activity
(proIL-1b), which is subsequently processed into 17-kDa mature highly-active IL-1b either
intracellularly by the caspase-1 inflammasome or extracellularly by other proteases (Dinarello,
2011). Intracellular processing and secretion generally require a second danger signal, such as
extracellular ATP via the P2X7 purinoceptor, potassium efflux, uric acid or reactive oxygen
species (Hoffman, 2009). This results in a non-classical secretion for cytoplasmic IL-1b that
bypasses the classic ER/Golgi glycosylation secretion pathway. Recent studies have shown that
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the pyroptosis regulator Gasdermin D (GSDMD) facilitates secretion of IL-1b from macrophages
that have activated inflammasome (Evavold et al., 2018). Once GSDMD is cleaved by the
inflammasome-associated proteases (Kayagaki et al., 2015), its N-terminal fragment oligomerizes
and forms large permeability pores in the plasma membrane through which IL-1b is released
(Heilig et al., 2018).

1.4. CD4 T Lymphocytes
CD4 T cells are essential modulators of an effective adaptive immune response. They play
a central role in various immunological processes, such as activation of cytotoxic T cells,
maturation of B cells into plasma cells and memory cells, enhancing microbiocidal activity of
macrophages, recruiting neutrophils, eosinophils and basophils to site of inflammation as well as
a crucial role in mediating tolerance and suppression of inflammatory responses (Luckheeram et
al., 2012; Zhu and Paul, 2008). T cell precursors develop from common lymphoid progenitors in
the bone marrow and migrate to the thymus for maturation. These T cell precursors rearrange their
chromosomal DNA in order to generate a large repertoire of T cell receptor specificities, followed
by a series of selection processes resulting in maturation into two distinct subsets, CD4 and CD8
T cells. The mature, receptor-specific T cells leave the thymus and circulate in the blood and
secondary lymphoid organs, constantly “looking” for antigens. T cells that have not been exposed
to antigen are termed as naïve. Human naïve CD4 T cells can be identified by the expression of TCell Receptor (TCR), CD4 co-receptor along with the expression of the surface molecule CD45
long isoform (CD45RA) and/or absence of the short isoform (CD45RO) (Berard and Tough, 2002).
The unique TCR receptor of each naïve CD4 T cell is responsible for its specificity and
only recognizes peptides presented by MHC class II molecules. Naïve CD4 T cells require two
signals for successful activation. The first signal is generated by the engagement of the TCR on

11

the naïve T cell with appropriate foreign peptide bound to the MHC class II molecule on the APCs.
The second signal is provided by co-stimulatory molecules such as B7 proteins (CD80 and CD86)
on the APCs that interact with CD28 co-receptor on the T cells (Smith-Garvin et al., 2009). This
second signal promotes the survival and clonal expansion of the T cells following the activation
process (Acuto and Michel, 2003). During TCR activation, the CD4 T cells depending mainly on
the particular cytokine microenvironment can differentiate into several CD4 subsets such as T
Helper 1 (Th1), Th2, Th17, T regulatory cells and follicular helper T cells with a variety of immune
functions (Zhu et al., 2010).
Monocytes, macrophages and dendritic cells are the major sources of IL-1b (Asgari et al.,
2013). Recent studies have shown that under specific conditions, both the Human and Mouse CD4
T cells express low levels of the proIL-1b protein (Arbore et al., 2016; Doitsh et al., 2014; Martin
et al., 2016). However, these reports have not explored the transcriptional status of the IL1B gene
in the CD4 T cells. Previous studies have reported that the Spi1 transcription factor that is
absolutely necessary for IL1B gene expression in monocytes is expressed in double-negative
CD4/8 T cells, but it is lost in double-positive and naïve CD4 T cells (Rothenberg et al., 2013).
Upon differentiation, Spi1 is shown to be re-expressed in Th2 (Chang et al., 2005) and Th9 (Chang
et al., 2010) CD4 T cells. Yet, it has not been known whether IL1B gene expression in CD4 T cells
is dependent upon the Spi1 transcription factor.
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2.1. ABSTRACT
Interleukin 1β is a pro-inflammatory cytokine important for both normal immune responses
and chronic inflammatory diseases. The regulation of the 31 kDa proIL-1β precursor coded by the
IL1B gene has been extensively studied in myeloid cells, but not in lymphoid-derived CD4 T cells.
Surprisingly, we found that some CD4 T cell subsets express higher levels of proIL-1β than
unstimulated monocytes, despite relatively low IL1B mRNA levels. We observed a significant
increase in IL1B transcription and translation in CD4 T cells upon ex vivo CD3/CD28 activation,
and a similar elevation in the CCR5+ effector memory population compared to CCR5− T cells in
vivo. The rapid and vigorous increase in IL1B gene transcription for stimulated monocytes has
previously been associated with the presence of Spi-1/PU.1 (Spi1), a myeloid-lineage transcription
factor, pre-bound to the promoter. In the case of CD4 T cells, this increase occurred despite the
lack of detectable Spi1 at the IL1B promoter. Additionally, we found altered epigenetic regulation
of the IL1B locus in CD3/CD28–activated CD4 T cells. Unlike monocytes, activated CD4 T cells
possess bivalent H3K4me3+/H3K27me3+ nucleosome marks at the IL1B promoter, reflecting low
transcriptional activity. These results support a model in which the IL1B gene in CD4 T cells is
transcribed from a low-activity bivalent promoter independent of Spi1. Accumulated cytoplasmic
proIL-1β may ultimately be cleaved to mature 17 kDa bioactive IL-1β, regulating T cell
polarization and pathogenic chronic inflammation.
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2.2. INTRODUCTION
ProIL-1β, the interleukin 1β protein precursor, is encoded by the IL1B gene within an IL1
family gene cluster located on human chromosome 2. ProIL-1β is principally produced by
activated monocytes/macrophages. These cells become activated by pathogen-associated molecule
patterns (PAMPs) recognized by pattern recognition receptors (PRRs), and/or secondary damage
signals (DAMPs, danger-associated molecular patterns) (Eder, 2009; Petrilli et al., 2007).
Following activation, proIL-1β is synthesized as a precursor protein with very low biological
activity. It is then processed into highly active mature IL-1β, either intracellularly by the caspase1 inflammasome or extracellularly by other proteases (Dinarello, 2011; Dubyak, 2012; Malhotra,
2013). Most of our current understanding of IL1B transcriptional and translational regulation stems
from studies of myeloid-lineage cells. IL1B gene expression has not extensively been examined in
lymphoid cells.
Spi-1/PU.1 (Spi1) is a transcription factor involved in genome-wide development and
maintenance of cells in the macrophage lineage (Lawrence and Natoli, 2011). Spi1 often associates
with inducible transcription factors, such as NF-kB and C/EBPβ, on lipopolysaccharide (LPS)responsive promoters and enhancers in human and murine macrophages (Ghisletti et al., 2010;
Heinz et al., 2010). In the monocyte/macrophage lineage, Spi1 constitutively binds to the IL1B
promoter at two distinct sites located between -50 to -39 and -115 to -97 relative to the transcription
start site (Adamik et al., 2013; Kominato et al., 1995). In non-myeloid cells, its ectopic expression
can result in IL1B transcription in the presence of an activation signal for NF-kB and C/EBPβ
(Adamik et al., 2013; Kominato et al., 1995; Shirakawa et al., 1993). Additionally, Spi1 can act as
a “pioneer factor”, binding nucleosome-occluded DNA and facilitating chromatin accessibility for
LPS-responsive transcription factors in activated monocytes (Marecki et al., 2004; Natoli, 2012).
Further, it directly recruits TATA-binding protein (TBP), which is involved in forming the pre-
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initiation complex (PIC) that helps to recruit RNA Polymerase II (Pol II) to gene promoters
(Adamik et al., 2013; Hagemeier et al., 1993).
IL-1b is expressed at extremely high levels in myeloid-derived cells in response to
microbial invasion and tissue injury (Adamik et al., 2013). Although activated monocytes are a
major source of IL-1b; NK cells, B cells, dendritic cells, fibroblasts, and epithelial cells also
express this protein, but at much lower levels (Libby et al., 1986). ProIL-1β has been previously
detected in human lymphoid CD4 T cells expressing chemokine receptor 5 (CCR5+) (Doitsh et
al., 2014). This proIL-1β can be cleaved and released as highly active mature IL-1β following
abortive HIV infection. Recent reports have further shown that stimulation of the T cell antigenreceptor (TCR), when combined with varied co-stimulation can induce the production of proIL-1b
in CD4 T cells. Specifically, mouse CD4 T cells that were TCR-activated in vitro by CD3/CD28
crosslinking were found to produce proIL-1b mRNA and protein (Martin et al., 2016). Human
CD4 T cells also produced high levels of proIL-1β when CD3 stimulation was combined with antiCD46 complement receptor activation (Arbore et al., 2016). This study further showed that NLRP3
inflammasome activation in these cells caused cleavage of proIL-1β to highly bioactive mature
IL-1b form, supporting polarization of type-1 T-helper cells in an autocrine manner (Arbore et al.,
2016). While these studies highlight the biologic importance of lymphocyte-derived IL-1β, little
is known about the regulation of the IL1B gene in CD4 T cells.
As stated above, IL1B transcription depends on the Spi1 transcription factor, which is
highly expressed in monocytes. However, it is not known whether proIL-1b expression depends
on Spi1 in CD4 T cells. The status of IL1B gene transcription and its epigenetic landscape in
lymphoid CD4 T cells is also unknown. Thus, we set out to measure the regulation of IL1B in
lymphoid-derived CD4 T cells, including Pol II and Spi1 engagement and specific epigenetic
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marks on IL1B chromatin, in both ex vivo CD3/CD28-activated CD4 T cells and in vivo
differentiated memory CCR5+ CD4 T cells isolated from human lymph nodes.

2.3. RESULTS
2.3.1. Human lymphoid T cells express proIL-1b after T cell antigen-receptor activation.
To better understand the process of proIL-1b expression in lymphoid CD4 tonsillar T cells,
anti-CD3/CD28 beads were used in order to stimulate the T cell antigen receptors. After three days
of activation, IL1B mRNA substantially increased in the ex vivo-activated tonsillar CD4 T cells,
as compared to unstimulated T cells and the THP-1 human monocytic cell line, a well-studied
benchmark population for IL1B gene expression, as well as the negative control human kidney
epithelial HEK293 (Figure 2A). The mRNA kinetic profile for IL1B revealed highest transcription
after 3 days following the CD3/CD28 activation (Figure 3A). However, LPS-treated THP-1 cells
expressed approximately 500-fold more IL1B mRNA than the 3-day CD3/CD28 activated CD4 T
cells. Of note, the level of SPI1 mRNA, which encodes Spi1, a myeloid-lineage transcription factor
required for vigorous IL1B gene expression in activated monocytes (Adamik et al., 2013), was
slightly increased following the activation of CD3/CD28 on CD4 T cells (Figure 2B and 3B),
although Spi1 protein was undetectable (Figure 2C). By contrast, THP-1 monocytes expressed
high levels of constitutive SPI1 mRNA and protein, which did not increase after LPS treatment.
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Figure 2. CD4 T cells express proIL-1β following TCR stimulation. Relative mRNA expression
for (A) IL1B and (B) SPI1 in purified CD4 T cells from human lymphoid tissue (two individual
patient donors), stimulated for 3 days with anti-CD3/CD28 beads, compared to resting CD4 T cells,
HEK293 cells, and THP-1 cells (unstimulated or LPS-treated for 1.5 h). Data were normalized to
the HEK293 cell sample; Standard error for each donor from lymphocyte populations represents
technical replicates, and control cell lines (HEK293 and THP-1) represents biological replicates.
(C) Western blot analysis of proIL-1β and Spi1 proteins from samples shown in A and B. The
proIL-1β and Spi1 blots are shown at short and long exposures to illustrate the relative abundance
of these proteins in CD4 T cells. Membranes were stripped and re-probed for β-actin. Note that
the β-actin levels vary between cell types and increases with TCR stimulation. Sample inputs for
western blots were normalized by cell equivalents: 1.5x105 for all lanes. For conciseness and
clarity, only cropped western blot images are displayed. The full-length images of these blots are
provided in Appendix A1.1.

Figure 3. CD4 T cells express maximal IL1B mRNA after 3 days of TCR activation. Kinetic
mRNA profile for (A) IL1B and (B) SPI1 in CD4 T cells following the TCR activation for indicated
time. The values were normalized to HEK293 negative control cells. For comparison, unstimulated
THP-1 cells are shown, which express low levels of IL1B mRNA and constitutive SPI1.

18

Western blot analysis revealed that CD3/CD28 activated T cells expressed substantially
higher levels of proIL-1b compared to their unstimulated counterparts (Figure 2C). Importantly,
unstimulated THP-1 monocytes did not express proIL-1b protein (Figure 2C). As expected, CD4
T cells expressed much lower levels of proIL-1b protein than LPS-treated THP-1 monocytes.
Together, these results demonstrate that antigen receptor stimulation of human CD4 lymphocytes
can induce de novo expression of IL1B gene transcription and protein synthesis. Flow cytometry
analysis for proIL-1b revealed maximal protein after 3 days of CD3/CD28 activation with
significant increase in induction over naïve T cells after 1 day of activation (Figure 4D). This flow
cytometry analysis also revealed that increase in proIL-1b production in activated CD4 T cells is
likely from majority of the T cells expressing the protein at low levels and not from few high
producers (Figure 4E). Interestingly, among the CD3/CD28 activated T cells, proIL-1b is produced
by both CCR5+ and CCR5− cells (Figure 4F).

Figure 4. Characterization of ex vivo differentiated CD4 T cells. (A) Fresh human PBMCs
were isolated and analyzed by flow cytometry and compared to CD4 T cells, which were
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magnetically purified by negative selection from tonsil. Note the lack of monocytes in CD4 T cell
preparations. (B&C) Purified CD4 T cells from tonsil, stimulated with anti-CD3/28 beads or
resting for 3 days of culture were surface-stained for CD45RO (memory marker), CCR5, and
CD25. TCR stimulation induces an activated memory phenotype, including upregulation of CD25
and CD45RO, and homogenous increase of CCR5. (D) Time course showing increasing proIL-1β
following CD3/CD28 activation (blue traces). Cells were stimulated with anti-CD3/28 beads for
time indicated, then treated with GolgiPlug (BD Biosciences) for two hours, surface stained as
described in Methods, then fixed and permeabilized (eBiosciences Cytofix/Perm). Intracellular
proIL-1β was stained using Alexa647 anti-IL-1β (BioLegend). Shown here are representative
cytograms from one donor, representative of four individual donors. (E) Increase in proIL-1β
production among the activated T cells is likely from almost all cells; not the result of a few high
producers. (F) Among CD3/CD28 activated T cells, proIL-1β is produced by both CCR5+ and
CCR5- cells (gated as in E).
Previous work has shown that CCR5+ cells express proIL-1b protein, which can be cleaved
and released during pyroptotic cell death (Doitsh et al., 2014). In vivo CCR5+ CD4 T cells are
predominantly effector memory cells, expanded from previous antigen-mediated activation.
Lymphoid-derived CCR5+ and CCR5− CD4 T cells were purified from fresh human tonsil tissue
by sequential magnetic and flow sorting (Figure 5A). All preparations of these cells were
completely devoid of monocytes (Figure 4A). Cells from six donors were combined and compared
with negative control HEK293 cells, as well as both unstimulated and LPS-stimulated THP-1 cells.
IL1B mRNA was approximately 15-fold higher in CCR5+ CD4 T cells than their CCR5−
counterparts (Figure 5B). Interestingly, IL1B mRNA was much lower in CCR5+ T cells than
unstimulated THP-1 monocytes, which express measurable levels of IL1B mRNA (Kaspar and
Gehrke, 1994). SPI1 mRNA was also slightly higher in CCR5+ cells than in CCR5− T cells (Figure
5C). As previously described (Adamik et al., 2013), THP-1 monocytic cells expressed high levels
of constitutive SPI1 mRNA, independent of LPS stimulation. Western blot analysis revealed that
CCR5+ T cells expressed higher levels of proIL-1b protein than CCR5− T cells, unstimulated
THP-1, and HEK293 cells (Figure 5D). Anticipating that LPS-treated THP-1 cells would produce
high levels of proIL-1b protein, lysate for this positive control was loaded at one-tenth of that used
for all other samples. This revealed an intense band for proIL-1b protein at ~31 kDa for LPS-
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treated THP-1. Again, proIL-1b protein was completely undetectable in unstimulated THP-1 cells
but was present in CCR5+ CD4 T cells (Figure 5D). This result contrasts with the 25-fold greater
abundance of IL1B mRNA in unstimulated THP-1 compared to CCR5+ T cells (Figure 5B),
reflecting different mechanisms of post-transcriptional regulation of IL1B mRNA between these
two cell types.

Figure 5: in vivo differentiated CCR5+ CD4 T cells express proIL-1b. (A) Shown is a
representative flow-sort from an individual CCR5+ CD4 T cell isolation. Cells were sorted from
the CCR5+ and CCR5- gates as shown, after performing negative-selection magnetic enrichment
of CD4 T cells from fresh human tonsil. Relative mRNA expression levels for (B) IL1B and (C)
SPI1 from CCR5+ and CCR5- CD4 T cells, HEK293 cells, and both unstimulated and LPSstimulated THP-1. For mRNA analysis, multiple donors were pooled and the standard error
represents technical replicates. The standard error for THP-1 and HEK293 reference samples were
calculated from biological replicates. (D) Western blot for proIL-1b from cells prepared as above
described for two individual patient donors. Samples were normalized by cell equivalents: 1.5x104
cell equivalents for THP-1+LPS and 1.5x105 in all other lanes. Membranes were stripped and reprobed for β-actin. The β-actin band for LPS stimulated THP-1 is not visible on the blot because
only 1/10th of the cells were added to prevent over-saturation of pro-IL1β band. For conciseness
and clarity, only cropped western blot images are displayed. The full-length images of these blots
are provided in Appendix A1.2.
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2.3.2. Spi1 is not a detectable regulator of IL1B gene transcription in activated T cells.
To further understand de novo transcription of IL1B after CD3/CD28 activation of CD4 T
cells, the presence of Pol II and Spi1 on the IL1B gene was investigated using chromatin
immunoprecipitation-quantitative

PCR

(ChIP-qPCR).

Amplicons

for

chromatin

immunoprecipitation (ChIP) were designed to span the IL1B promoter and structural gene in order
to measure the enrichment profile for Pol II and Spi1, as previously described (Adamik et al., 2013)
(Figure 6A). We found that RNA Polymerase II (Pol II) on the IL1B gene in ex vivo CD3/CD28activated T cells was substantially enriched at the promoter and throughout the gene body,
compared with unstimulated CD4 T cells (Figure 6B). Pol II engagement was not detected on the
IL1B gene in negative control HEK293 cells. As expected, LPS-treated THP-1 monocytes had the
highest levels of Pol II at both the promoter and throughout the body of the gene.

Figure 6. Occupancy of Pol II and Spi1 on the IL1B gene. (A) Gene schematics with exons
labeled as Roman numerals, and qPCR amplicons indicated by Arabic numbers referenced to
positions listed in Table 2. (B) Pol II and (C) Spi1 ChIP for indicated CD4 T cell populations. For
comparison, IL1B-refractory HEK293 cells were used as a negative control, and THP-1 cells
stimulated with LPS for 1.5 hours were used as a positive control. CD4 T cells were purified from
human lymphoid tissue and activated for 3 days with anti-CD3/CD28 beads and compared to
unstimulated CD4 T cells. Promoter-proximal amplicons are shown as green bars, whereas
downstream amplicons are shown as gray scale bars. Standard error for each donor from
lymphocyte populations represents technical replicates, and control cell lines from cultured
biologic replicates. (D) Histone H3 nucleosome ChIP at IL1B promoter in ex vivo CD3/CD28activated and unstimulated CD4 T cells as described within, are qualitatively compared to the
previously reported Spi1 binding site and nucleosome distribution at the IL1B promoter in THP-1
cells (Adamik et al., 2013). This reveals that a nucleosome is positioned over the Spi1 recognition
22

site in T cells. It has also been reported that Spi1-binding displaces this histone in THP-1 cells, but
not in both Spi1-negative 293 cells and the HUT102 T cell line (Adamik et al., 2013). The qPCR
amplicons used are listed in Table 2.

Figure 7. The Spi1 independent IL1B gene for in vivo differentiated CCR5+ CD4 T cells
exhibits similar bivalent H3K4me3+/H3K27me3+ epigenetic marks as ex vivo TCR-activated
CD4 T cells. (A) Shown is a flow-sort from six individual donors pooled together to separate
CCR5+ and CCR5- CD4 T cells for ChIP analyses. Cells were sorted from the CCR5+ and CCR5gates as shown, after performing negative-selection magnetic enrichment of CD4 T cells from
fresh human tonsil. (B) Pol II and (C) Spi1 ChIP on IL1B gene was performed in these CD4 T cell
populations. For sake of comparison, Pol II and Spi1 ChIP data for HEK 293 and LPS stimulated
THP-1 cells are included. (D&E) Actively transcribing HIST1H4K gene from the same chromatin
was used as control. Histone modification ChIP on IL1B and HIST1H4K genes in CCR5+ and
CCR5- CD4 T cell populations: (F) H3K9Ac; (G) H3K4me3; (H) H3K27me3; and (I) H3K36me3.
Gene schematics for IL1B and HIST1H4K genes with exons labeled as Roman numerals are
provided in Figure 6A and 8A respectively. Promoter-proximal amplicons are shown as green bars,
whereas downstream amplicons are shown as gray scale.
In monocytes, Spi1 constitutively binds at the IL1B promoter and is required for
transcription (Adamik et al., 2013). Because SPI1 mRNA was slightly up-regulated in CD4 T cells
after ex vivo CD3/CD28 activation, Spi1 protein engagement at the IL1B promoter was measured.
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Spi1 protein was not enriched at the promoter region of IL1B in either CD3/CD28-activated or
CCR5+ CD4 T cells, when compared to the body of the gene (Figure 6C and 7C). This is supported
by the lack of detectable Spi1 protein in T cells (Figure 2C). Spi1 was also not substantially
enriched at the promoter in IL1B-refractory HEK293 cells. However, Spi1 was more abundant at
the promoter of LPS-stimulated THP-1 cells than at the downstream gene body (Figure 2C).
Histone H3 ChIP nucleosome profiles were also generated for the IL1B promoter in activated CD4
T cells and compared to THP-1 cells from our previous work (Adamik et al., 2013). These revealed
that both unstimulated and stimulated primary T cells, like HEK293 and Hut102 T cells (Adamik
et al., 2013), possess a nucleosome positioned over the Spi1 binding site, supporting a Spi1independent model for IL1B gene transcription in CD4 T cells (Figure 6D).

2.3.3. IL1B is transcribed from a bivalent H3K4me3/H3K27me3 promoter in CD3/CD28activated T cells.
The ex vivo CD3/CD28-activated lymphoid CD4 T cells were examined for the presence
of chromatin marks that correlate with either permissive/active or repressed/inactive genes at the
IL1B locus. Specifically, H3K4me3 and H3K9ac at promoter-proximal regions are generally
associated with actively transcribed genes (Wang et al., 2008), whereas H3K27me3 is generally
associated with inactive genes (Hansen et al., 2008). Additionally, H3K36me3 located at
downstream regions of genes is generally associated with active transcript elongation by Pol II
(Henikoff and Shilatifard, 2011).
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Figure 8. CD3/CD28-stimulation of CD4 T cells induces bivalent H3K4me3+/H3K27me3+
marks. Histone modification ChIP analysis of IL1B in CD3/CD28-activated and unstimulated
CD4 T cell populations from two donor samples as indicated: (A) H3K9Ac; (B) H3K4me3; (C)
H3K27me3, and (D) H3K36me3. The qPCR amplicon designations for panels A-D are as
described in Figure 6A. Histone modification ChIP of the HIST1H4K (H4) gene in ex vivo
CD3/CD28-activated and resting CD4 T cell populations as indicated: (F) H3K9Ac; (G)
H3K4me3; (H) H3K27me3; and (I) H3K36me3. The qPCR amplicon designations for panels F-I
are as shown in (E). Promoter-proximal amplicons are shown as green bars, whereas downstream
amplicons are shown as gray scale. H3K9ac levels at the IL1B promoter are approximately half of
HIST1H4K in activated CD4 cells. H3K4me3 is much lower on IL1B. Note that the inhibitory
mark, H3K27me3, is substantially reduced on the IL1B gene following TCR activation, but not as
low as it is on HIST1H4K in the same cells. Standard error for each donor represents technical
replicates.
Following ex vivo CD3/CD28 activation, the H3K9ac and H3K4me3 marks substantially
increased (Figure 8A and B), consistent with transcriptional activity. The H3K27me3 repressive
mark only slightly decreased (Figure 8C), while the H3K36me3 mark increased along the length
of the gene, indicating ongoing transcription (Figure 8D). However, comparing these IL1B histone
modifications to those of constitutively expressed “housekeeping” HISTH4K gene in the same
cells, the activating H3K9ac and H3K4me3 marks were approximately 2- and 4-fold lower,
respectively, on IL1B than HISTH4K (Figure 8F and G). Also, the repressive H3K27me3 mark is
10 to 12-fold higher on IL1B in activated T cells than on HISTH4K in the same cells (Figure 8H).
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Together, these findings of intermediate levels for both activating and inhibitory marks support a
“bivalent” status for the IL1B promoter in CD4 lymphocytes following activation.
The epigenetic status of the IL1B gene in CCR5+ and CCR5− CD4 T cells was also
investigated; revealing a slightly enriched H3K9 acetylation at the IL1B promoter in CCR5+ CD4
T cells (Figure 7F). Both active H3K4me3 and repressive H3K27me3 were also enriched in
CCR5+ CD4 T cells (Figure 7G and H), a characteristic of low-activity bivalent promoters (Voigt
et al., 2013). In contrast, CCR5− CD4 T cells exhibited the H3K27me3, but not the active
H3K4me3 mark at the IL1B promoter. Histone H3K36me3 was not substantially different on IL1B
in either CCR5+ or CCR5− populations (Figure 4I). The control “housekeeping” HIST1H4K gene
for both activated CCR5+ and naïve CCR5− cells revealed a promoter signature characteristic of
actively expressed genes (H3K4me3+/H3K27me3Low), with CCR5− revealing higher levels of
H3K4me3 than CCR5+ (Figure 7G and H). Histone H3K36me3 revealed the classic increase of
gene body over promoter at the transcriptionally active HIST1H4K gene (Figure 7I).

2.4. DISCUSSION
Recent findings of proIL-1b production and functionality in CD4 T cells highlight the
importance of lymphocyte-derived IL-1b, a previously unappreciated phenomenon. We set out to
investigate the regulation of the IL1B gene expression in CD4 T cells, as previous reports have all
focused on these processes in myeloid-lineage cells. In the absence of stimulation, low-level IL1B
transcription in resting monocytic cells does not result in IL-1b protein expression because of a
specific post-transcriptional translation blockade (Kaspar and Gehrke, 1994) (Figure 2).
LPS-TLR-stimulation of THP-1 cells causes a massive increase in IL1B transcription, overcoming
the post-transcriptional block, resulting in abundant translation of proIL-1b. By contrast, the vast
majority of unstimulated lymphoid CD4 T cells have little or no IL1B transcription, while TCR
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activation causes de novo transcription and translation of IL1B to proIL-1b (Figure 2A and C,
Figure 3A). It is important to note that the low expression of proIL-1b protein in CD4 T cells is
not from few high producers but from a majority of the activated cells expressing the protein at
low levels (Figure 4E). Interestingly, both CCR5+ and CCR5− CD4 T cells are expressing
proIL-1b after 3 days of CD3/CD28 activation. Thus, it is likely that proIL-1b expression is
induced independently of CCR5, following TCR activation.
Previous studies demonstrated that vigorous IL1B transcription in activated monocytes has
an absolute requirement for the myeloid lineage-determining Spi1 transcription factor (Adamik et
al., 2013). Although Spi1 is expressed in early stage, pre-commitment (CD4/8 double-negative)
thymocytes, it is lost in CD4/8 double-positive and single-positive naïve T cells (Rothenberg et al.,
2013). Spi1 can be re-expressed in polarized Th2 (Chang et al., 2005) and Th9 (Chang et al., 2010)
cells, suggesting that it may play a role in the regulation of IL1B gene expression following
activation of CD4 T cells. Accordingly, we sought to compare the status of Spi1 involvement in
IL1B gene transcription for activated CD4 T cells. Although, a slightly higher level of SPI1 mRNA
was observed in activated T cells, when compared to resting T cells and HEK293 cells, Spi1
protein was not detected in any of these cells (Figure 2C). Consistent with the role of Spi1 as a
required monocyte-macrophage lineage commitment factor for IL1B transcription (Adamik et al.,
2013), its basal expression in both unstimulated and LPS-treated THP-1 monocytes were very high
when compared to HEK293 and CD4 T cells. The very low level of proIL-1b protein in activated
T cells, as compared to LPS-treated THP-1 monocytes, suggested a potentially distinct mechanism
for IL1B gene transcription in T cells. The significant increase of Pol II at the promoter and body
of the IL1B gene in activated T cells revealed by ChIP-qPCR provides further support for de novo
IL1B transcription following TCR activation (Figure 5B). Consistent with the mRNA observations,
this level of Pol II engagement at the IL1B gene is much lower than that observed on LPS-treated
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THP-1 cells, resulting in substantially lower IL1B gene transcription in T cells than in activated
monocytes. Additionally, Spi1 ChIP did not reveal enrichment at the IL1B promoter in activated
T cells, arguing that transcription of IL1B in lymphocytes is Spi1-independent. This result is in
striking contrast to monocytes, for which IL1B gene expression is absolutely dependent on Spi1
and THP-1 cells exhibit a robust constitutive presence of Spi1 at the canonical DNA recognition
site on the IL1B promoter (Adamik et al., 2013) (Figure 5C).
Additionally, the IL1B promoter in both unstimulated and activated T cells reveals strong
nucleosome enrichment positioned directly over the Spi1 DNA binding site (Figure 6D), consistent
with the lack of involvement of Spi1 in CD4 T cell transcription of IL1B. We have previously
reported the presence of a stable nucleosome directly over the Spi1 binding site at the IL1B
promoter in the Hut102 T cell line that does not express IL1B mRNA (Adamik et al., 2013). The
winged helix-turn-helix (wHTH) DNA binding domain of Spi1, like other wHTH proteins
(Iwafuchi-Doi et al., 2016), possesses potential “pioneer” activity for opening chromatin by
nucleosome displacement. Consequently, the presence of a strong nucleosome signal over the high
avidity Spi1 DNA binding sequence at the IL1B promoter is consistent with the absence of Spi1
activity in CD4 T cells.
As previously demonstrated (Doitsh et al., 2014), the majority of CD4 T cells producing
proIL-1b in vivo are marked by expression of the chemokine receptor CCR5 (Figure 5D).
Interestingly, the relative IL1B mRNA expression in CCR5+ lymphocytes, though 15-fold higher
than their CCR5− counterparts, was lower than that of unstimulated THP-1 monocytes. This
observation is consistent with previous studies demonstrating that the IL1B gene is transcribed
from a Spi1-poised promoter in unstimulated THP-1 monocytes (Adamik et al., 2013) that
expresses a low basal level of IL1B mRNA (Chanput et al., 2010). Despite active transcription of
IL1B in unstimulated THP-1 cells, the intracellular proIL-1b protein level in CCR5+ CD4 T cells
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was higher. This finding is not surprising, since unstimulated monocytes are known to exhibit a
constitutive background level of IL1B mRNA transcript in the absence of detectable protein, due
to a translational blockade that is reversed by LPS treatment (Kaspar and Gehrke, 1994). Therefore,
if CCR5+ CD4 T cells lack a post-transcriptional blockade, a low-level translation of proIL-1b
may occur as a result of a low level of IL1B transcription. Supporting a model of low IL1B
transcription rate in CCR5+ cells, we detected only slight Pol II enrichment at IL1B promoterproximal regions, as compared to CCR5− CD4 T cells (Figure 7B), but differences in Pol II
enrichment between these T cells populations were not detected throughout the length of the IL1B
gene body, as observed in CD3/CD28 ex vivo activated T cells. The same chromatin samples were
also evaluated for the actively transcribed HIST1H4K housekeeping gene. Both CCR5+ and
CCR5− cells showed significant engagement of Pol II on HIST1H4K (Figure 7D). Although Pol
II is likely transcribing IL1B at a very low level, over time, accumulation from low-rate
transcription/translation could explain the substantial pool of intracellular proIL-1b detected in
CCR5+ CD4 T cells (Figure 5D).
As observed following ex vivo CD3/CD28 activation, SPI1 gene mRNA levels were
slightly higher in CCR5+ cells than in both CCR5− and HEK293 cells. However, in light of the
lack of detectable Spi1 in activated CD4 T cells (Figure 2C) and negative detection of Spi1 on the
IL1B promoter in CCR5+ CD4 T cells (Figure 7C), it is unlikely that Spi1 is responsible for the
low level IL1B transcription observed in CCR5+ CD4 T cells in vivo.
It is well established that CCR5+ CD4 T lymphocytes are the primary cellular targets of
HIV infection (Bleul et al., 1997; Eckstein et al., 2001; Jekle et al., 2003; Roy et al., 2005;
Schweighardt et al., 2004). However, in ex vivo cultures from fresh human tonsil or spleen tissues
(Glushakova et al., 1995), the majority of these cells are non-permissive for HIV replication, with
the cytosolic viral DNA intermediates initiating an innate immune response that leads to the
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activation of caspase-1. This results in abortive HIV infection (Doitsh et al., 2010), along with the
death of abortively-infected CD4+ T-cells via caspase 1-mediated pyroptosis (an inflammatory
form of programmed cell death) (Doitsh et al., 2014). As a result, dying CCR5+ CD4 T cells
release mature IL-1β protein into the extracellular space, potentially driving a localized
inflammatory response (Doitsh et al., 2014). Such an inflammatory response likely drives a vicious
pathogenic cycle, where pyroptotic CD4 T cells release bioactive IL-1b and inflammatory
mediators including chemokines that attract more cells into the infected lymph nodes to die,
driving even more inflammation (Doitsh and Greene, 2016).
Resident CCR5+ CD4 T cells in lymphoid tissues are primarily memory cells. Unlike naïve
CD4 T cells (which do not express CCR5), these CCR5+ CD4 T cells have previously undergone
TCR activation before developing into activated/memory T cells. As our results show that
CD3/CD28 activation of resting CD4 cells drives proIL-1β expression, it is likely that CCR5+
cells express proIL-1β as a consequence of prior, in vivo TCR activation. Memory CD4 T cells
continually recirculates within lymphoid tissues, scanning for presentation of their cognate antigen
(Lanzavecchia and Sallusto, 2000; Mackay, 1993; Sallusto et al., 1999). CCR5 expression has
been previously characterized as a marker of Th1 lymphocytes (Loetscher et al., 1998). CCR5+
CD4 T cells could contribute substantially to chronic inflammation through activation of caspase1 and release of bioactive IL-1b.
Our previous work explored epigenetic regulation of IL1B in myeloid cells (Adamik et al.,
2013). Genes in embryonic and hematopoietic stem cells (Roh et al., 2006; Shen and Orkin, 2009;
Vaquerizas and Torres-Padilla, 2016), as well as differentiated T cells (Roh et al., 2006), have
been previously reported to be marked by active and repressive histone modifications, with the
ratio of these marks modulating gene transcription. The new evidence presented in this study
suggests that the IL1B gene in CD4 T cells following TCR-activation is modified to a bivalent
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H3K4me3+/H3K27me3+ status (Figure 8) that likely supports of a low level of transcriptional
activity (Voigt et al., 2013). By contrast, the IL1B gene in unstimulated T cells is marked solely
by high levels of monovalent H3K27me3 (i.e., no detectable promoter-localized H3K4me3). This
supports the observed lack of IL1B transcription in naïve/unstimulated T cells. Additionally, a
substantially higher level of H3K9ac is observed at the IL1B promoter in activated CD4 T cells,
supporting active transcription. Finally, progressively increasing H3K36me3 through the IL1B
gene body is consistent with ongoing, de novo Pol II transcription (Adamik et al., 2013). These
marks in activated CD4 T cells differ from myeloid cells: unstimulated THP-1 cells possess
monovalent H3K4me3, the active mark, which increases along with H3K9ac when stimulated with
LPS (Adamik et al., 2013).
Validation of our results is found in the epigenetic analysis of the short, intronless
HIST1H4K gene from the same chromatin samples. This “housekeeping” gene is actively
transcribed, displaying high-level monovalent H3K4me3, with minimal enrichment of H3K27me3
in both resting and activated T cells (Figure 8). Also, as expected for a constitutively active gene,
strong enrichment for H3K9ac was observed at the HIST1H4K promoter, and H3K36me3
increased towards the 3’ end of the gene body. Notably, the histone marks associated with
transcriptional activity were all substantially higher on the constitutively expressed HIST1H4K
gene than the IL1B gene from the same activated T cell chromatin samples. The repressive
H3K27me3 histone mark at the IL1B promoter is much higher than that on the HIST1H4K gene,
supporting the model that IL1B in activated T cells is transcribed from a low-activity bivalent
H3K4me3+/H3K27me3+ promoter. The Spi1-independent nature of T cell IL1B expression may
explain this observation, whereas Spi1 activity in monocytes supports monovalent H3K4me3+ and
high transcription.
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Furthermore, the epigenetic study of CCR5+ T cells also reveals a bivalent profile at
(H3K4me3+/H3K27me3+) of the IL1B promoter. Similar to unstimulated CD4 T cells, the IL1B
gene in CCR5− cells contains only high levels of monovalent H3K27me3, the transcriptional
repressive mark (Figure 7G and H). Also, the H3K36me3 comparison did not reveal a progressive
increase toward the 3’ end of the IL1B, as was observed in ex vivo activated T cells. H3K36me3
did present a classic profile for the HIST1H4K gene in both CCR5+ and CCR5− cell types. It is
striking that the relative level of modification for this mark throughout IL1B in both CCR5+ and
CCR5− T cells is comparable and appears elevated throughout the gene with respect to that of
HIST1H4K. Interestingly, literature suggests that H3K36me3 modification patterns are not
exclusively associated with gene activation, and can be related to other processes (Wagner and
Carpenter, 2012). Consequently, although the pattern of this modification did not provide
information on the transcriptional status of IL1B in either CCR5+ or CCR5− T cells, it is not
evidence against active IL1B transcription in CD4 T cells. Generally, the epigenetic studies of
CCR5+ vs. CCR5− CD4 T cells were limited by the low amounts of primary T cell chromatin
samples with six donor samples being pooled in order to generate sufficient material for analysis.
In conclusion, we have extended the current understanding of IL1B gene transcription in
human CD4 T lymphocytes, by investigating the involvement of Spi1 and the nature of chromatin
organization for the IL1B gene in these newly recognized cellular sources of IL-1b protein
expression. The proposed model argues that the IL1B gene in TCR-activated CD4 T cells is
transcribed

from

a

low-activity

bivalent

(H3K4me3+/H3K27me3+)

promoter

in

a

Spi1-independent fashion that results in the accumulation of intracellular proIL-1b (Figure 9). By
contrast, myeloid cells transcribe the IL1B gene constitutively at a low level in a Spi1-dependent
manner but have a post-transcriptional block on translation. TLR activation of monocytes drives
extreme transcription of Spi1-dependent IL1B, while releasing translation inhibition. These
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findings are highly relevant to further our understanding of adaptive immunity, since CD4
lymphocytes, as a source of IL-1b, can shape immune response polarization and inflammation in
disease.

Figure 9. Monocytes and T cells have distinct mechanisms for IL1B gene regulation. LPStreated monocytes have high levels of active monovalent H3K4me3 ( ) but lack inhibitory
H3K27me3 ( ) epigenetic histone modifications at the IL1B promoter. These modifications, along
with activated NF-kB and C/EBPβ (Adamik et al., 2013), drive a vigorous Pol II engagement with
extremely high transcriptional activity ( ) and correspondingly high levels of cytoplasmic proIL1β protein (•••). Unstimulated monocytes contain lower levels of monovalent H3K4me3 at the
IL1B promoter and are deficient in inhibitory marks, resulting in weak Pol II engagement and
extremely low transcription levels compared to stimulated monocytes. Accumulation of proIL-1β
in these cells is inhibited due to a translational blockade (X). The myeloid competence factor, Spi1
( ), is constitutively bound at a constant level to the IL1B promoter in these cells (Adamik et al.,
2013). In contrast to the immediate-early LPS responsive IL1B gene in monocytes, slowlyactivated developmentally-regulated genes possess bivalent promoters with both active H3K4me3
and inhibitory H3K27me3 epigenetic histone modifications. The IL1B promoter in lymphoid
CCR5+ CD4 T cells contains such a bivalent H3K4me3+/H3K27me3+ mark, resulting in decreased
Pol II engagement and substantially lower (~25‑times) transcription activity, as compared to
resting monocytes. Interestingly, despite such a low level of transcription, intracellular proIL-1β
accumulates in CCR5+ CD4 T cells in amounts higher than unstimulated monocytes. CCR5- CD4
T cells exclusively contain the inhibitory H3K27me3, which does not support active IL1B
transcription until after the engagement of the T cell receptor (TCR).
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2.5. MATERIALS AND METHODS
2.5.1. Cell Culture, Reagents and Treatment Conditions
Cell lines were obtained from American Type Culture Collection (ATCC). THP-1 cells were
cultured in RPMI media (Cellgro) supplemented with 10% heat-inactivated fetal bovine serum
(Hyclone), 1% Penicillin/Streptomycin Solution (Cellgro) and 500 μl of 2-mercaptoethanol
(Invitrogen). HEK293 cells were grown in EMEM (Cellgro) containing 10% heat-inactivated fetal
bovine serum and 1% Penicillin/Streptomycin Solution. In mRNA and ChIP analysis, THP-1 cells
were stimulated with 1ug/ml of E.coli 055:B5 Lipopolysaccharide (LPS) (L2880, Sigma-Aldrich)
for 1.5 hours. Human tonsils were obtained from the Cooperative Human Tissue Network and
processed as previously described (Doitsh et al., 2014; Galloway et al., 2015). Briefly, single cell
suspensions were prepared and purified by density gradient-centrifugation with Ficoll-Paque
Hypaque (GE Healthcare Life Sciences). CD4 T cells were enriched by negative selection using
EasySep Human CD4+ T Cell Enrichment Kits (STEMCELL Technologies), per the
manufacturer’s protocol. Following isolation, cells were cultured in RPMI (Gibco), plus 10% heatinactivated FBS (Atlas) and 1X Penicillin/Streptomycin/L-Glutamine (Gibco). For CD3/CD28
stimulation, anti-CD3/CD28 magnetic beads (Dynabeads, Thermo Fisher Scientific) were added
at a ratio of one bead per cell. Ex vivo anti-CD3/CD28 treatment of CD4 T cells results in antigenindependent activation of the CD3 T cell receptor and the CD28 co-receptor. This is in contrast to
normal in vivo activation involving cellular presentation of antigen by major histocompatibility
complex II to the T cell receptor complex, in the context of costimulatory and cytokine signals.

2.5.2. Cell Sorting and Flow Cytometric Analysis
Human tonsils were obtained from the Cooperative Human Tissue Network and processed
as previously described (Doitsh et al., 2014; Galloway et al., 2015). These tissue specimens are
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de-identified before receipt by the laboratory and have been classified exempt from human
subject’s research by the Human Research Protection Program Institutional Review Board of the
University of California, San Francisco. Briefly, single cell suspensions were prepared and purified
by density gradient-centrifugation with Ficoll-Paque Hypaque (GE Healthcare Life Sciences). For
ChIP analyses, CD4 T cells were isolated from HLAC by positive selection using CD4 microbeads
(Miltenyi) per manufacturer’s protocol. Isolated CD4 T cells were stained with APC-CD4,
APC/Cy7-CD3, and PE-CCR5 (clone 2D7/CCR5) (BD Biosciences) on ice for 3 hours. Stained
cells were sorted using FACSAriaII (BD Biosciences) to isolate CD3+CD4+CCR5+, and
CD3+CD4+CCR5− T cell populations.
For ChIP analyses the sorted cells were cross-linked immediately with 1% formaldehyde
(as described below) and pellets were stored at -80 °C. For mRNA analyses cells were lysed in
TRIzol (Invitrogen). For protein analyses, CD4 T cells were enriched by negative selection using
EasySep Human CD4+ T Cell Enrichment Kits (STEMCELL Technologies), per the
manufacturer’s protocol. The CD4 T cells were labelled on ice for 30 minutes with APC/Cy7-CD3,
PE/Cy7-CD4, and Brilliant Violet 421-CCR5 (BioLegend). The cells were then FACS sorted as
above. Sorted cells were lysed with RIPA buffer: 50mM Tris (Sigma), 150 mM NaCl (Sigma),
0.1% SDS (BioRad), 0.5% sodium deoxycholate (Sigma), 1% Triton X100 (Sigma), and Complete
protease inhibitor (Roche), and the lysates were frozen at -80°C.

2.5.3. Western Blot Analysis
Cell lysates prepared as above were loaded in 4-12% Bis-Tris NuPAGE gels
(ThermoFisher) for gel electrophoresis and transferred to PVDF membrane (EMD Millipore).
Membranes were blocked for 1 hour at room temperature in blocking buffer: PBS + 0.05%
Tween20 (Sigma) + 5% non-fat dry milk (BioRad). Primary antibodies were diluted in blocking
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buffer and incubated overnight at 4°C. ProIL-1b was detected by a C-terminal-reactive mAb at 1
µg/mL (mAb 201, R&D Systems). Blots were washed and probed with secondary Goat AntiMouse IgG, Human ads-HRP (SouthernBiotech), diluted 1:20,000 in PBS + 0.05% Tween20 + 5%
bovine serum albumin (Axenia BioLogix) for 2 hours at room temperature. HRP was detected
using Western Lightning ECL Pro Enhanced Luminal Reagent (PerkinElmer) and Hyperfilm ECL
(GE/Amersham).

2.5.4. mRNA Expression Analysis
1x106 THP-1 and HEK293 cells were plated into 6-well plates (Thermo Fisher). Following
the LPS treatments, cells were pelleted and supernatant was removed. The cell pellet was resuspended in 500 μl of TRIzol reagent (Invitrogen). For ex vivo differentiation experiments, naïve
or anti-CD3/CD28-treated T cells were cultured for 3 days, counted, and 5x106 cells were
resuspended in 500 µL of TRIzol reagent. For in vivo analyses, T cells were sorted, as described
above, and 5x106 CCR5− cells and 2x106 CCR5+ cells were immediately resuspended in 500 μl
of TRIzol reagent. Following the addition of 170 μl of Chloroform (Fisher), the samples were
vortexed well and incubated at room temperature for 15 minutes. Then, the samples were
centrifuged at 13200 RPM for 15 minutes at 4oC. Aqueous layer was transferred into a fresh tube
and combined with 500 μl of isopropanol (Fisher) and 1 μl of Glycogen (Ambion). The samples
were incubated at room temperature for 10 minutes and then centrifuged at 13200 RPM for 10
minutes at 4oC. The RNA pellets were washed with 500 μl of 75% Ethanol (Pharmaco-AAPER)
and centrifuged for 10 min in room temperature at 14000 RPM. Then, the ethanol was aspirated,
and the pellets were allowed to air-dry for 10-15 minutes. Air-dried pellets were re-suspended in
25 μl of DEPC-treated water (Ambion). The samples were incubated at 65oC for 10 minutes and
subjected to DNAse treatments using Turbo DNA-free reagents (Ambion) according to the
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manufacturer instructions in order to eliminate genomic DNA contamination. RNA concentration,
260/280 and 260/230 values were measured using NanoDrop 1000 spectrophotometer (Thermo
Fisher). mRNA was converted into cDNA using GoScript Reverse Transcription System (A5001,
Promega). cDNA was analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus
Applied Biosystems Real Time Instrument (Thermo Fisher). Relative expression levels were
calculated using DCt method. Primer Sequences used for mRNA analysis are indicated in Table 1.
Gene

Forward Primer

Reverse Primer

hIL1B

TCCAGGGACAGGATATGGAG

TCTTTCAACACGCAGGACAG

hSpi1

CCAGCTCAGATGAGGAGGAG

AGGCGGATCTTCTTCTTGCT

Table 1. Primer sequences used for mRNA analysis. Table shows qPCR forward and reverse
primers used for Human IL1B and Spi1 mRNA expression analysis.
2.5.5. Chromatin Immuno-precipitation (ChIP)
ChIP was performed using a modification of the Millipore/Upstate protocol
(MCPROTO407). In brief, a total of 1x107 THP-1 monocytes, 2.5x107 naïve CD4 T cells, 2.5x107
CD3/CD28-activated CD4 T cells, 5.9x107 CCR5− CD4 T cells and 1.58x107 CCR5+ CD4 T cells
were fixed in 1% formaldehyde (Fisher) for 10 min at room temperature. Cross-linking was
inhibited by addition of glycine to a final concentration 0.125 M. Cell pellets were washed twice
with ice cold PBS and resuspended in SDS Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris,
pH 8.1) supplemented with Protease inhibitor cocktail (Sigma) and 1mM phenylmethylsulfonyl
fluoride (PMSF, Fluka). Samples were sonicated (to generate DNA fragments of 250 base pairs
(bp) average length) on ice using a Fisher Scientific Sonic Dismembrator (Model 100), as follows:
15x25 strokes at 100% power followed by 3x25 stokes at 50% power and centrifuged at 12000
RPM for 10 min. Chromatin was diluted 7-fold in ChIP Dilution Buffer (0.01% SDS, 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH8.1, 167 mM NaCl. Total equivalence of 3x106
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cells was used for Pol II and Spi1 pull downs for both ex vivo and in vivo CD3/CD28-activated T
cells. For histone modifications ChIP analyses, 3x106 cells were used for ex vivo whereas 1.5x106
cells were used for in vivo CD3/CD28-activated CD4 T cells. Supernatants were incubated at 4°C
overnight with Santa Cruz antibodies Pol II (sc-899x), PU.1 (sc-352x), control IgG (sc-2027x);
Active Motif antibodies H3K9ac (61251), H3K4me3 (39915), H3K27me3 (39155), H3K36me3
(61101) and Cell Signaling Technology antibody Histone 3 (9715S). Aliquots for INPUT and nonspecific IgG control samples were included with each experiment. Samples were precipitated using
25 µl of Magna ChIP Protein A+G Magnetic beads, at 4°C for 3 hours, and subsequently washed
with following solutions: once with Low-Salt Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA,
20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once with High-Salt Buffer (0.1% SDS, 1% Triton X100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 550 mM NaCl), once with LiCl Wash Buffer (0.25
M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1mM EDTA, 10 mM Tris, pH 8.1), and twice
with TE Buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Immunocomplexes were eluted for 4
hours at 65°C with 200 µl of ChIP Elution Buffer (1% SDS, 0.1M NaHCO3). To reverse the crosslinking, eluted samples were treated with 10 µl of 5 M NaCl and subsequently incubated at 65°C
for ≥4 hours. DNA was purified using a GeneJET PCR Purification kit (K0702, Thermo Scientific).
Primer Sequences used for ChIP analysis are indicated in Table 2. The size of the PCR products
ranges between 80 and 150 bp. Twenty micro liter qPCR reactions containing 2x Maxima SYBR
Green/ROX qPCR Master Mix (Thermo Scientific), 250 nM of primers, and 3 µl of precipitated
DNA were set up in Fast 96-Well Reaction Plates (Applied Biosystems). qPCR reactions were
carried out in a StepOnePlus Applied Biosystems Real Time Instrument. Fold enrichment was
calculated based on Ct as 2(DCt), where DCt = (Ct Input – Ct IP). Final enrichment values were adjusted
by subtraction of the nonspecific IgG antibody binding.
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IL1B
Position Forward Primer
(Number)
-279
TGTGTGTCTTCCACTTTGTCCCAC
-223

TGTGGACATCAACTGCACAACG

-155

TTGCTACTCCTTGCCCTTCCATGA

-91
(0)

CCCTAAGAAGCTTCCACCAATAC
TC

-19
(1)
+36
(2)
+98

ACAACTAGGTGCTAAGGGAGTC

Reverse Primer
CCTGACAATCGTTGTGCAGTTGAT
G
TTCATGGAAGGGCAAGGAGTAGC
A
GAGTATTGGTGGAAGCTTCTTAG
GG
GCAGAAGTAGGAGGCTGAGAAA

AAACCTCTTCGAGGCACAAG

AGGAGAGGGAGAGACAGAGAAA
GA
GAGCAATGAAGATTGGCTGA

CAGCCAATCTTCATTGCTCA

GCATACACACAAAGAGGCAGAG

+160

CTCTGCCTCTTTGTGTGTATGC

GAGGGAAGGAGAGGGAGAGA

+223

TCTCCCTCTCCTTCCCTCTC

TTCCCAGAATATTTCCCGAGT

+271

GCCAGGTGTAATATAATGCTTAT
GACTCGG
TGCACTGGATGCTGAGAGAAA

GACACTAACCTTTAGGGTGTCAG
C
GGCTGCTTCAGACACCTGTG

AATCTCCGACCACCACTACAGCA
A

AAGGGAAAGAAGGTGCTCAGGTC
A

+5389
(5)

ACTGCTGTGTCCCTAACCACAAG
A

TTCAACACGCAGGACAGGTACAG
A

+6268
(6)

TCGCTGCAGAGTGTAGATCCCAA
A

TGCTTGAGAGGTGCTGATGTACC
A

+505
(3)
+3325
(4)

HIST1H4K
Position
(Number)
+35
(7)
+237
(8)
+382
(9)

Forward

Reverse

GACTCCTCTTGCTCGTCATGTCTG

CGCCTTTGCCAAGACCCT

GGTGCTGAAGGTGTTCCTGG

CGCTTGGCGTGCTCTGTA

GGTTGAGCGTCCCTTTCTATCAACA TGGGCAAACAAGCATCACGG

39

Table 2. Primer sequences used for ChIP analysis. Table shows Human IL1B and HIST1H4K
primer sequences used for ChIP. Numbers indicate the midpoint of amplicons in relation to the
Transcription start site. Arabic numbers in red indicate the amplicons number in reference to gene
schematic in Figure 6A and 8E.
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3.1. ABSTRACT
We previously reported that transcription of the human IL1B gene, encoding the
proinflammatory cytokine interleukin 1b, depends on long-distance chromatin looping that is
stabilized by a mutual interaction between the DNA-binding domains (DBDs) of two transcription
factors, Spi-1 proto-oncogene (Spi1) at the promoter and CCAAT enhancer–binding protein b
(C/EBPb) at a far-upstream enhancer. We have also reported that the C-terminal tail sequence
beyond the C/EBPb leucine zipper is critical for its association with Spi1 via an exposed residue
(Arg-232) located within a pocket at one end of the Spi1 DNA-recognition helix. Here, combining
in vitro interaction studies with computational docking and molecular dynamics of existing X-ray
structures for the Spi1 and C/EBPb DBDs, along with the C/EBPb C-terminal tail sequence, we
found that the tail sequence is intimately associated with Arg-232 of Spi1. The Arg-232 pocket
was computationally screened for small-molecule binding aimed at IL1B transcription inhibition,
yielding L-arginine, a known anti-inflammatory amino acid, revealing a potential for disrupting
the C/EBPb:Spi1 interaction. As evaluated by chromatin immunoprecipitation, cultured
lipopolysaccharide (LPS)-activated THP-1 cells incubated with L-arginine had significantly
decreased IL1B transcription and reduced C/EBPb’s association with Spi1 on the IL1B promoter.
No significant change was observed in direct binding of either Spi1 or C/EBPb to cognate DNA
and in transcription of the C/EBPb-dependent IL6 gene in the same cells. These results support the
notion that disordered sequences extending from a leucine zipper can mediate protein–protein
interactions and can serve as druggable targets for regulating gene promoter activity.
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3.2. INTRODUCTION
Human interleukin 1β (IL-1β), a member of the IL-1 family of cytokines coded by the IL1B
gene, is an important mediator of inflammation in response to microbial invasion and tissue injury.
Many rapidly induced/immediate early (IE) genes such as FOS and EGR1 (Donner et al., 2010),
TNF (Adamik et al., 2013) and a majority of the 6,511 protein genes in human K562 cells (Pugh
and Venters, 2016) possess prebound RNA Polymerase II (Pol II) co-present with TATA Binding
Protein (TBP) and TFIIB transcription pre-initiation factors paused 30-50 bp upstream of the
transcription start site. In contrast, we previously reported that the human IL1B gene promoter is
deficient in prebound Pol II and constitutively binds the Spi1/PU.1 (Spi1) transcription factor in
the almost complete absence of TBP and Pol II (Adamik et al., 2013). Spi1, which is required for
IL1B gene expression in monocytes (Adamik et al., 2013), is a myeloid cell lineage-determining
factor that has a C-terminal ETS family winged Helix-Turn-Helix (wHTH) DNA binding domain
(DBD) and an N-terminal transactivation domain (TAD). We also reported that the DNA binding
domain of constitutively promoter-bound Spi1 directly interacts by long-range chromatin looping
(Adamik et al., 2013) with the DBD of the C/EBPβ transcription factor, which in-turn binds to a
far upstream super-enhancer following Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4)
signaling. The critical protein–protein interaction between Spi1 and C/EBPβ in monocytes occurs
along with TBP and Pol II recruitment, gene expression, and an apparent chromatin loop
stabilization (Adamik et al., 2013; Listman et al., 2005; Yang et al., 2000). We have also reported
that the C-terminal tail extension of the C/EBPb basic leucine zipper (bZIP) is critical for
C/EBPb:Spi1 association via an exposed arginine residue (Arg-232) within a pocket at one end of
the DNA-recognition helix in the Spi1-DNA X-ray structure (Listman et al., 2005) previously
reported by others (Kodandapani et al., 1996).
In an attempt to investigate the molecular nature of this critical protein–protein interaction,
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computational docking of the existing independent X-ray structures for the C/EBPb and Spi1
DBDs yielded a conformation reminiscent of a C/EBPb:cMyb X-ray structure previously reported
by others (Tahirov et al., 2002). Although the cMyb structure provided a basis for a C/EBPb:Spi1
interaction, the absence of the C/EBPb C-terminal tail suggested a distinct binding mode for
C/EBPb with Spi1. In vitro interaction studies between the DBDs of the two proteins argues for a
larger surface footprint on Spi1 than would be expected for a cMyb-like interaction with C/EBPb.
Our docking of the isolated C/EBPb C-terminal tails to Spi1 revealed an intimate association of
the terminal cysteine carboxylate of the tail with Arg-232 of Spi1. A composite C/EBPb:Spi1
structure was then generated and evaluated by molecular dynamics simulation, revealing a stable
structure consistent with the new and previously reported data.
In order to test the computational model, the Arg-232 pocket in the Spi1:DNA X-ray
structure (Kodandapani et al., 1996) was used to screen known small molecules for competitive
potential. L-arginine, a known anti-inflammatory, was computationally identified to bind in this
pocket, suggesting a potential for disrupting the C/EBPb:Spi1 interaction. Subsequent ex vivo
studies using LPS-activated THP-1 cells incubated with L-arginine demonstrated a significant
decrease in IL1B transcription in parallel with a reduction in C/EBPb association with Spi1 on the
IL1B promoter, as evaluated by chromatin immunoprecipitation. No significant change was
observed for parallel transcription of the Spi1-independent/ C/EBPb-dependent IL6 gene.
Importantly, direct binding of Spi1 and C/EBPb to cognate DNA was unaffected. These results
are consistent with an L-arginine-dependent decrease in IL1B gene expression being due to its
ability to inhibit the protein–protein interaction between C/EBPb and Spi1 in the absence of any
effect on direct DNA binding for either factor.
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3.3. RESULTS AND DISCUSSION
3.3.1. Computational modeling predicts interaction between the C/EBPβ leucine zipper
C-terminus and the Spi1 DNA binding domain
Our previous reports described a long-range DNA loop-mediated promoter-proximal
protein–protein interaction between the Spi1 winged Helix-Turn-Helix (wHTH) DNA binding
domain (DBD) and the carboxyl end of the C/EBPβ leucine zipper dimer DBD that is critical for
IL1B gene transcription (Adamik et al., 2013; Listman et al., 2005; Yang et al., 2000). This
interaction is similar to that which we reported for Human Cytomegalovirus (HCMV) IE2 protein
with Spi1 (Wara-aswapati et al., 1999) and by others for C/EBPa with GABPa (Shimokawa et al.,
2010; Shimokawa et al., 2013; Shimokawa and Ra, 2005). Although the structure of HCMV IE2
protein is unknown, the structures of the Spi1 and GABPa DBDs are known and represent the two
most distantly related ETS wHTH DBDs of the 12 ETS domain homology types (Hollenhorst et
al., 2011). The ETS family of DNA binding proteins all contain a common ETS DBD localized to
either end or the middle of the overall protein sequence (Hollenhorst et al., 2011). The structure of
several ETS domains have been solved, all of which contain three interacting a-helices, one of
which serves as a DNA sequence recognition element, along with two loops closed by antiparallel
b-strands that constitute a wing motif that provides additional DNA backbone interactions. An
HTH structure is also found in other DNA binding domains that possess a similar 3 a-helix
backbone without b-strands and minimal sequence conservation with the ETS subfamily. Three
tandem copies of the non-ETS HTH domains are contained within the cMyb DNA binding protein,
which also binds the C/EBPβ leucine zipper dimer. The X-ray crystal structure of the C/EBPβ
leucine zipper coiled-coil attached to its basic (i.e., positively charged) DNA binding sequence
interacting with DNA-bound cMyb (a DNA:bZIPC/EBPβ:HTHcMyb:DNA complex) reveals a
C/EBPβ bZIP dimer interaction with a single cMyb HTH domain (Tahirov et al., 2002). In this
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structure, the short C-terminal peptide tails that extend beyond each of the leucine zipper
monomers were deleted, resulting in the C-terminal glutamate of one bZIP monomer and a second
glutamate within the body of the zipper generating salt bridges to one cMyb DBD (Figure 10).

Figure 10. Three rotational views of the DNA:bZIPC/EBPβ HTHcMyb:DNA interaction
generated from the RCSB-deposited coordinates using transformations provided in the 1H89
PDB file. The C/EBP bZIP homodimer (Chain A, Green & Chain B, Blue) joins two separate
DNA duplexes (Grey) by directly interacting with one of the two DNA-bound cMyb HTH domains
(Red) via both truncated C-terminal ends of the leucine zipper dimer (aa296 to 336) in the absence
of the 9 amino acid C-terminal extra-zipper tails (aa337 to 345), while also interacting via the bZIP
basic DNA binding domain (aa259 to 295) to a second DNA. Chain B also makes direct contact
with a DNA backbone phosphate, indicated by an arrow in the upper right structure.
The structure of the C/EBPβ:cMyb complex provides a potential paradigm for other
bZIP:HTH domain interactions. This resulted in our earlier studies aimed at exploring the
involvement of the C/EBPβ leucine zipper C-terminal glutamate (Listman et al., 2005) and a
detailed inspection of the contact surface between the two domains that were generated from the
RCSB-deposited X-ray coordinates using transformations described within the 1H89 PDB file
(Figure 10). The C/EBPβ:cMyb contact surface consists of an asymmetric interaction between the
C-terminus of the C/EBPβ leucine zipper dimer and a single cMyb HTH domain involving 4 side
chain, 1 backbone and 9 van der Waals contacts with the bZIP Chain A, along with 5 backbone, 2
van der Waals contacts and 2 DNA salt-bridge interactions with the bZIP Chain B (Tahirov et al.,
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2002; Tsukada et al., 2011). Strikingly, the leucine zipper dimer extra-ZIP C-terminal peptides,
each consisting of 9 residues beyond the terminal Glu-336 were deleted from the molecule used
for crystallography, providing circumstantial evidence that complex formation did not require
sequences beyond the structural terminus of the bZIP dimer. This conclusion appeared to agree
with the hypothesis provided in our previous report (Listman et al., 2005) that suggested Glu-336
might directly interact with Arg-232 of Spi1 for the C/EBPβ:Spi1 interaction, although the
importance of the Chain B DNA contact was never addressed. Consequently, we set out to attempt
computational docking in order to evaluate possible requirements for the C/EBPβ:Spi1 interaction.
The initial computational approach took advantage of the ZDOCK webserver (Pierce et al.,
2014), which uses rigid-body protein–protein docking via a fast Fourier transform algorithm that
relies on a combination of shape complementarity, electrostatics and statistical potential. The
C/EBPβ bZIP, basic leucine zipper, sequence from aa266 to 336 was docked to the Spi1 DBD.
Figure 11 displays models for the 8 top-ranking zipper dimer interactions, all of which reveal tight
clustering to a localized target on the surface of Spi1 for the carboxyl ends of the C/EBPβ zipper
dimer coiled-coil. Six of these ZDOCK predictions involve at least one salt-bridge between
C/EBPβ and Spi1, three of which are with the terminal C/EBPβ Glu-336. All of these interactions
absolutely depend upon the terminal Glu-336 residue, since C/EBPβ aa266 to 335, missing this
residue, did not yield a consistent result (Figure 12). This docking geometry, lacking the extra-ZIP
C-terminal unstructured peptides, resembles the C/EBPβ:cMyb interaction (Tahirov et al., 2002)
and did not provide structural evidence for the involvement of Arg-232 (Figure 11, red arrow),
which we previously reported to be essential for the interactions (Listman et al., 2005).
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Figure 11. Computational docking using the ab initio ZDOCK server. Six different views of a
composite backbone ribbon structure presenting the general orientation of the top eight C/EBPb
leucine zipper coiled-coil dimers (long Blue coils representing aa296 to 336) with an invariant
Spi1 DBD, represented as three a-helices (short Blue coils) and four b-strands (Red bands). The
Spi1 a3 DNA-recognition helix in two views is labeled with a red arrow pointing to the location
of Arg-232 (R232). A green arrow locates the position of the amino end of the Spi1 DBD (residue
171). The first 170 N-terminal residues of the full length Spi1 protein Transactivation domain
(TAD) is not contained within the solved X-ray structure. The four structures in the top row are
related by incremental 90o rotations, whereas the lower row presents top and bottom views. Due
to its flexible behavior in the absence of DNA, the aa266 to 295 DNA-binding basic regions of the
bZIP, is not shown in the figure.

Figure 12. ZDOCK docking between Glu 336-deficient C/EBPβ (aa296 to 335) and Spi1. The
figure reveals the almost random docking in the absence of Glu 336.
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Since the ZDOCK prediction does not rely on experimental data, we employed the
HADDOCK webserver, which provides a data-driven approach to docking by requiring a list of
residues that are either Active (involved) or Passive (potentially involved) in contact as part of the
data input (de Vries et al., 2010). Data for HADDOCK was obtained using an in vitro glutathioneS-transferase (GST) interaction approach, as we had previously used for gross mapping of DNAindependent Spi1 interactions with HCMV IE2 (Wara-aswapati et al., 1999) and seven other
proteins (Adamik et al., 2013). The GST results (Figure 13A and B) collectively suggest that the
C/EBPβ leucine zipper independently targets specific substructures within the Spi1 wHTH ETS
domain. In particular, we focused on helix a3, which contains Arg-232 (Figure 13A, white band),
and the wing loop component interaction between the b3 and b4 anti-parallel strands. An
additional interaction may also localize to the b1 and b2 antiparallel strands, which together with
b3 and b4 constitute a complete wHTH wing module (Figure 13B). Figure 13C presents these
interacting regions as backbone (Top) and space-filling (Bottom) views of the Spi1 DBD bound
to DNA and color coded with respect to indicated regions in Figure 13A, revealing that one side
of the structure may be the most relevant for C/EBPb interaction (Figure 14). This information
was used to specify Active and Passive residues for HADDOCK docking between the full-length
aa259-336 bZIP dimer (that included the N-terminal basic DNA-binding motif) and the Spi1
wHTH domain, as described in Materials and Methods. The C/EBPβ C-terminal 7 amino acids (aa)
of the leucine zipper dimer (aa330-336), which terminates at Glu-336, was defined as active,
whereas the N-terminal DNA-binding region (aa259-295) was defined as passive. The Spi1b3/b4
anti-parallel strands that include the interpositioned loop located between aa243 and aa254 were
defined as active, while the sequence between aa171 and aa219 was made passive. The resulting
HADDOCK interaction appeared similar, but not identical, to that obtained with ZDOCK (Figure
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15), once again supporting a C/EBPβ:cMyb-like interaction. In particular, salt bridges between
Glu-336 in C/EBPβ Chains A and B with the sidechains of Lys-248 and Lys-244 in Spi1,
respectively, are consistent with both the cMyb tail-less mode of docking and the ZDOCK result
in the absence of Glu-336 (Figure 12). Unfortunately, neither ZDOCK nor HADDOCK provide
direct evidence for the involvement of the C-terminal tails and, specifically, Arg-232. However,
the GST interaction results (Figure 13) suggest that the Spi1 a3 helix, containing Arg-232, may
be a part of an extended contact surface for the Chain B C-terminal tail.

Figure 13. Summary of Glutathione-S-Transferase (GST) interaction studies between the
C/EBPb leucine zipper (aa259 to 345) and the Spi1 DBD. The location of Arg-232 in the a3
helix is indicated by a white band. (A) Schematic representation and relative binding of GST-Spi1
ETS-domain DBD fragments to 35S-methionine-labeled C/EBPb leucine zipper. (B) SDS
polyacrylamide gels presenting the degree of interaction by autoradiography (Top). The relative
amount of input protein by staining with Coomassie Brilliant Blue is shown (Bottom). (C) X-ray
crystal structure (RCSB 1PUE) of Spi1 bound to DNA (Grey space-filled) presenting specific GST
protein–protein interaction results shown as blue and green structural elements, as indicated in A,
with their general location on backbone ribbon (Top) and space-filling (Bottom). The Arg-232
sidechain is shaded red and the location of the N-terminal Lysine of the Spi1 DBD is labeled (K171).
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Figure 14. Rotational views of Spi1:DNA correlating specific GST protein-protein
interaction results. The single structural view in Figure 13C is expanded in order to present
multiple views more clearly demonstrating the asymmetrical interaction of C/EBPβ on Spi1. The
interacting regions are shown as blue and green structural elements in A with their general location
on backbone ribbon (Top) and space-filling models of Spi1 bound to DNA (Grey space-filled).
The Lys 171 amino terminus of the Spi1 DBD and the Arg 232 sidechains are shaded red.

Figure 15. Computational docking using the data-driven HADDOCK server. Two views of
the top four docking solutions for the C/EBPb leucine zipper coiled-coil dimer (Red coils) to Spi1
(Pink surface) bound to DNA (Grey surface). The diagram to the right presents the interactions
between Spi1 DBD and each C/EBPb (aa266 to 336) chain.
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3.3.2. A critical salt bridge between C/EBPβ and Spi1 is stable throughout the NAMD
simulation
In order to model the Arg-232 interaction, an independent approach was used for docking
of the C/EBPβ C-terminal extra-zipper tails. This involved the use of LowMode MD (Labute,
2010), a method of short molecular dynamics simulations to predict the likely orientation of protein
loops. The resulting LowMode MD docking of the C/EBPβ C-terminal extra-zipper tails revealed
a salt-bridge between the side-chain guanidinium group of Arg-232 in the Spi1 a3 helix and the
C-terminal carboxylate group of Cys-345 on the Chain B C/EBPβ tail (Figure 16A), consistent
with our previous report suggesting that Arg-232 on Spi1 is critical for the interaction between the
two proteins (Listman et al., 2005). The Chain A tail docked into a pseudo-symmetrical location
on the Spi1 a3 Helix, interacting with Lys-224 (Figure 16B).

Figure 16. LowMode Molecular Dynamics docking of C/EBPβ extra-leucine zipper Cterminal tail to DNA-bound Spi1. (A, Left) The Spi1 DBD and the C/EBPβ 20 amino acid
peptide sequence from T326 to C345, which includes the last eleven amino acids of the leucine
zipper and the nine amino acids of the C-terminal tail, are presented as a ribbon/coil backbone with
sidechain sticks. DNA is shown as a grey surface. Spi1 R232 and C/EBPβ C345, which constitute
the specific interaction between the two proteins, are presented as ball & stick atoms. (A, Right)
Interaction schematics present the contact environment of the terminal Chain B C345 of C/EBPβ
in the Spi1 pocket. (B, Left & Right) Similar LowMode MD for docking of the C/EBPβ Chain A
extra-leucine zipper tail to DNA-bound Spi1.
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The LowMode MD Docking of the C/EBPβ C-terminal extra-zipper tails to the Spi1 DBD
was executed in the absence of the C/EBPβ leucine zipper:cMyb-like interaction in order to test
whether the two contacts were independent, an hypothesis derived from the apparent independent
targeting of specific substructures within the Spi1 wHTH ETS domain revealed by the in vitro
GST studies (Figure 13). Superimposition of the Chain A LowMode MD C/EBPβ C-terminal tail
structure revealed significant coincidence with the C/EBPβ Chain A leucine zipper monomer from
HADDOCK, permitting manual manipulation of the backbone in order to generate a peptide bond
(Figure 17). The Chain B LowMode MD Spi1 C-terminal tail structure was also reasonably close
to the Glu-336 terminus of the HADDOCK C/EBPβ Chain B, which was also computationally
attached to the tail.
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Figure 17. General structural geometry relationships among the HADDOCK, Low Mode
MD and NAMD docked C/EBPβ:bZIP structures. (A) Display of two merged Spi1 DBD
structures associated with either the Chain A C-terminal extra-zipper tail (aa332 to 345) LowMode
docking result (Green) or the ChainA:Chain B leucine zipper dimer derived from HADDOCK
docking (Red), showing the Chain B Glu336 interaction with Lys244 of Spi1. (B) Two 90o
rotational views, each displaying two merged Spi1 DBD associated with either the Chain A
(Green):Chain B (Red) leucine zipper dimer with C-terminal extra-zipper tails, derived from the
completed NAMD simulation or just the Chain A (aa332 to 345) LowMode docking, as indicated.
The dotted double-headed arrow indicates the distance between the Chain A Lys332 a-carbons
from the two models.
The resulting composite structure, consisting of: 1) the HADDOCK-derived bZIP dimer
docked to Spi1; 2) the two peptide-bonded LowMode-docked C-terminal extra-zipper tails; and 3)
both fragments of double-stranded DNA from the two original X-ray crystal structures was then
energy minimized. This resulted in the loss of the Chain A leucine zipper Glu-336 salt bridge and
a rotational movement of this chain with respect to Chain B. Since the in vitro data and LowMode
MD docking supported an interaction between Cys-345 of C/EBPb and Arg-232 of Spi1, the Chain
B tail was computationally replaced with the LowMode MD tail structure and the
Cys-345:Arg-232 contact constrained prior to energy minimization and solvation, following which
the constraints were removed and the structure was subjected to 104 ns of NAMD simulation.
Strikingly, the Glu-336 salt bridges that appeared critical for C/EBPb:cMyb-like docking in the
absence of the C-terminal tails were both destabilized in the presence of the Arg-232-docked Chain
C-terminal tail. The loss of the salt bridges was accompanied by a 13 Å displacement of the leucine
zipper dimer from its original HADDOCK location toward the Arg-232 side of the Spi1 DBD
(Figure 17B).
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Figure 18. NAMD simulation for the solvated completely docked Spi1:C/EBPβ with
C-terminal tails that generated the final structure shown in Figure 20A. (A) The inter-atom
distances for different conformations of the salt-bridge between Zeta carbon of Arg232 on Spi1
(Chain C) and C-terminal carboxylate carbon of Cys345 on C/EBPβ Chain B during the NAMD
run. The inter-atom distance between: (B) the Zeta 1 nitrogen of Lys224 on Spi1 (Chain C) and
backbone carboxylate carbon of Cys345 on C/EBPβ Chain A; (C) the Zeta nitrogen of Lys198 on
Spi1 (Chain C) and backbone carboxylate carbon of Cys345 on C/EBPβ Chain A; and (D) the Zeta
1 nitrogen of Lys 248 on Spi1 (Chain C) and sidechain carboxylate carbon of Cys336 on C/EBPβ
Chain A.

Figure 19. Detail of C/EBPβ:Spi1 contact surface showing the individual sub-interactions.
The 1481 Å2 surface consists of 928 Å2 from Chain B and 578 Å2 from Chain A (See Table 3).
The zipper-only contact is 274 Å2, while the Chain A and Chain B tails represent 320 and 912 Å2,
respectively. Overall, the Chain B tail that terminates in the critical Spi1 Arg 232 interaction
represents approximately 60% of the contact surface.
The stability of the Chain B interaction between Arg-232 of Spi1 and Cys-345 at the
C/EBPβ C-terminus was maintained (Figure 18A) vs that for the Chain A tail, which rapidly
destabilized during the first 20 ns of the simulation (Figure 18B) and folded into a compact domain
that directly interacted with the Spi1 DBD, providing 320 Å2 of buried contact surface (Figure 19)
along with a compensatory C-terminal Cys-345 salt bridge to Lys-198 of Spi1 (Figure 18C). The
resulting dynamically stable Chain B-biased model (Figure 20 and 21) is not only compatible with
our previously reported mutational (Listman et al., 2005) and GST (Figure 13) in vitro results, but
also suggests that the HADDOCK and Chain B interactions could be cooperative in a two-step
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docking model. This involves an initial HADDOCK cMyb-like C/EBPb Glu-336 ionic-driven
interaction, followed by reconfiguration to a more stable conformation involving the Chain B
C-terminal tail interaction with Arg-232 along with the increased excluded-water contact surface
and compensatory salt bridge of Chain A. In addition, the inability of the C/EBPβ Chain A
C-terminal tail to readily conform to the LowMode MD prediction during the NAMD simulation
conforms not only with the in vitro data, but also with reports of Spi1 interactions with C/EBPβ
homotypic heterodimers. These closely related CREB-CREM bZIP family heterodimers, which
possess a highly divergent collection of bZIP C-terminal extensions, binding to the IL1B gene
(Gray et al., 1993; Tsukada et al., 1994).

Figure 20. Details of the interaction between Spi1 and C/EBPβ resulting from NAMD
simulation. (A) Shows three views of the DNA-Spi1DBD:C/EBPbbZIP+Tails-DNA structure at
the end of the 104 ns NAMD simulation. The white dotted box in the bottom-side view locates the
region where the major Arg-232:Cys-345 and Arg-235:His-344 interactions occur between Spi1
and C/EBPb. The C/EBPb A and B chains are colored Red and yellow, respectively. Spi1 is
colored Blue. (B) Detailed structure of the interaction between Arg-232 of the Spi1 with Cys-345
at the C-terminus of C/EBPb Chain B and Arg-235 of Spi1 with His-344 of C/EBPb Chain B at
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the end of the NAMD run. Backbone colors are as described for Panel A. (C) Specific atomic
distances tracked during the NAMD simulation. The first plot (left) tracks inter-atom distances
between the Zeta carbon of Arg-232 on Spi1 and C-terminal carboxylate carbon of Cys-345 on the
C/EBPβ Chain B. The second plot (right) tracks inter-atom distances between the Eta1 nitrogen of
Arg-235 on Spi1 (Chain C) and the backbone carboxylate oxygen of His-344 on C/EBPβ Chain B.
(D) A modified figure derived from our previously published report (Listman et al., 2005)
demonstrating the relative importance of Arg-232 and Arg-235 as revealed by in vitro protein–
protein interaction studies.
The final NAMD conformation for the complex, including DNA fragments representing
the IL1B gene promoter and super-enhancer, reveals (Figure 20A) how the C/EBPβ:Spi1
interaction might stabilize a 2.8 Kbp chromatin loop between the IL1B promoter and its
super-enhancer (Adamik et al., 2013). In addition to the Arg-232:Cys-345 C-terminal C/EBPβ
interaction with Spi1, a proximal contact exists between His-344 of C/EBPβ and Arg-235 of Spi1
(Figure 20B). The NAMD reveals that both of these interactions are stable over the last 98 ns of
the simulation, with the Arg-232(Cz):Cys-345(CCO) contact stabilizing before that of
Arg-235(Nh1):His-344(OCO) (Figure 20C). This supports the kinetic importance of the
Arg-232:Cys-345 contact over that of Arg-235:His-344 and is consistent with our previous report
(Listman et al., 2005) experimentally demonstrating that mutation of Arg-232 in Spi1 was
substantially more critical for complex stability with C/EBPβ than Arg-235, as referenced in
Figure 20D. This previous study revealed that an Arg-232 point mutation alone reduced
C/EBPb:Spi1 interaction by about 80% (Listman et al., 2005). Figure 20B shows the
Arg-232:Cys-345 and Arg-235:His-344 interactions between Spi1 and C/EBPβ and their
respective O-N bond lengths at the end of the NAMD run. A weak salt bridge was observed
between Chain A of C/EBPβ (Cys-345) and Spi1 (Lys-198) only towards the end of NAMD
simulation (Figure 18C). Along with these interactions, some non-polar and hydrogen bonds were
also observed between Spi1 and C/EBPβ (Figure 21A and B).
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Figure 21. The Spi1:C/EBPβ interaction surface. (A) Structural interaction diagram shows the
key interacting residues in: C/EBPβ Chain A (Blue); C/EBPβ Chain B (Green); and Spi1 (Red).
The overall contact surface is marked by a yellow swath. H-bonds are indicated by black dots and
electrostatic interactions by blue dashes. (B) Summary of all intermolecular interactions between
Spi1 and C/EBPb.
The total 1481Å2 of buried surface area between Spi1 and C/EBPβ (Table 3) is within the
range of values that have been observed for other functional protein–protein interactions (Janin et
al., 2007). In particular, the C-terminal residues (337-345) of C/EBPβ Chain B contribute more
than half of the average buried surface area (912Å2) as compared to Chain A terminal residues,
whose average buried surface area with Spi1 is only 320Å2 (Table 3 and Figure 19). The interaction
between the guanidinium side chain of Arg-232 and the C-terminal carboxylate of Cys-345 is
noteworthy as a result of both its geometry and electrostatics. First, the arginine side chain has the
highest pKa (~12.48) of any amino acid, while the terminal cystine carboxylate presents the lowest
a-carboxyl pKa (~1.71), providing the strongest potential for a unitary salt bridge. In addition, the
bifurcated nature of the carboxylate-guanidinium interaction provides for a cooperative bidentate
linear geometry that has been exploited by many proteins (SAPSE and RUSSELL, 1984), with
59

stabilities that can approach -3.6 kcal/mol (Linton and Hamilton, 1999) and argued to provide
enzymatic active site stability in thermophilic organisms (Lam et al., 2011). Consequently, it may
not be surprising that the Arg-232:Cys-345 guanidinium:carboxylate interaction between the Spi1
DBD and the C/EBPβ Chain B C-terminal bZIP extension is a singularly critical component of the
observed complex stability (Listman et al., 2005). Strikingly, in contrast to the extended nature of
the Chain B interaction that positions Cys-345 in the DNA-protein pocket at the end of the Spi1
a3 DNA-recognition helix, the NAMD simulation positions the C-terminal extension of Chain A
beyond Glu-336 with the backbone of the following residue folded upon itself to form a globular
structure from Pro-337 through the terminal Cys-345 carboxylate that forms a salt bridge to Lys198 of Spi1 (Figure 21A). Globular folding of a C-terminal bZIP extension for protein–protein
interaction has previously been reported for the Epstein-Bar virus ZEBRA bZIP (Petosa et al.,
2006).

Table 3: Buried Surface area between C/EBPβ and Spi1. Shows the total buried surface area
between different regions of C/EBPβ and Spi1 at the end of the NAMD run in comparison to
previous reported buried surface area for C/EBPβ:cMyb (Tahirov et al., 2002) and other functional
protein-protein interactions (Janin et al., 2007).
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3.3.3. L-arginine reduces C/EBPβ binding to Spi1 on the IL1B gene promoter
The critical importance of Spi1 in TLR4-dependent induction of the human IL1B gene
(Adamik et al., 2013) suggests a unique and specific role in promoter regulation that could be
targeted for inhibition. Although specific inhibition of Spi1 binding to DNA by small molecules
has been explored (Munde et al., 2014), this approach suffers from its inability to discriminate
among the highly conserved Spi1-DNA binding sites, an important issue because Spi1 regulates
at least 219 genes (Turkistany and DeKoter, 2011) almost exclusively as a functional enhancer–
binding factor. However, the involvement of Spi1 as a promoter, rather than an enhancer, factor
for IL1B, as well as its unique mode of action in physically integrating C/EBPb bound to the farupstream C/EBPb super-enhancer into the promoter, suggests that disruption of this interaction
could provide a highly specific target for disrupting Spi1 action at the IL1B promoter.
Consequently, we used the Arg-232 interaction pocket between Spi1 and the C/EBPβ
Chain B extra-zipper C-terminal tail to screen existing public database libraries for small
compounds. It is important to note that this screening was conducted with the original 1PUE Spi1DNA X-ray structure (Kodandapani et al., 1996), independent of our C/EBPb docking models.
Only those compounds capable of competitive binding to this interaction pocket, without affecting
direct/cognate Spi1-DNA binding, were selected. One of the highest-scoring compounds resulting
from multiple computational docking trials was L-arginine, a common semi-essential amino acid.
Figure 22 presents interaction diagrams for one of the highest-scored L-arginine binding modes
docked into the Spi1:C/EBPβ Chain B interaction pocket. Interestingly, this mode involves
contacts with Arg-232 and Asn-236, closely mimicking the Cys-345 interaction with Spi1 from
NAMD (Figure 21B).
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Figure 22. A Potential binding mode for L-arginine docked into the Spi1:C/EBPβ Chain B
interaction pocket. (A) Two-dimensional interaction schematic and (B) three perspective views.
Locations of relevant amino acids, DNA backbone phosphates, and L-arginine are labeled. (C)
Pharmacophore model demonstrating the favorable accessibility and chemical interaction potential
for C/EBPβ Chain B over Chain A.
This potential inhibitory interaction of L-arginine with Spi1 was tested by examining TLRdependent de novo IL1B gene expression in cultured THP-1 cells in L-arginine-deficient RPMI
1640 media. The titration of L-arginine in the presence and absence of a 2.5 hr 1 μg/ml LPS
treatment revealed an inhibitory trend of IL1B gene expression between 5 and 50 mM L-arginine,
beyond the 1.15 mM concentration of conventional RPMI media. A 10 mM concentration was
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chosen for subsequent experiments because the lowest concentration generating a significant
change was 10 mM. At the highest concentration of 50 mM, cells exhibited an altered morphology,
although retaining viability (Figure 23A). Figure 23B demonstrates inhibition of IL1B
transcription with 10 mM L-arginine at various concentrations of LPS. In contrast to IL1B, the IL6
gene does not possess a Spi1-dependent promoter but is otherwise activated via similar TLRactivated transcription factors as IL1B (Baccam et al., 2003). Consequently, IL6 mRNA was
assayed in parallel with IL1B, revealing no significant decrease in the presence of L-arginine
(Figure 23B). Chromatin immunoprecipitation (ChIP) revealed an L-arginine-dependent decrease
in C/EBPβ binding to Spi1 at the critical promoter-proximal Spi1 binding site (Adamik et al., 2013)
on the human IL1B gene promoter. As a control, C/EBPb binding to promoter-bound Spi1 was
compared to a downstream site on the IL1B gene that does not bind either C/EBPβ or Spi1. The
PCR amplicon covering the Spi1 binding site on the IL1B promoter is centered at 19 nucleotides
upstream of the transcription start site (-19 relative to the TSS), while the PCR amplicon control
site is centered at +4858 nucleotides downstream of the TSS. Direct C/EBPβ binding to DNA was
also evaluated by ChIP at a well-known avid C/EBPβ binding site (Zhang et al., 1994) with a PCR
amplicon centered at -77 of the IL6 gene in the same cells. Incubation of THP-1 cells in the
presence of 10 mM L-arginine decreased C/EBPβ association with Spi1 at the critical -19 site on
the IL1B gene promoter following 2.5 hr LPS treatment (Figure 23C). Under these conditions there
was no significant effect on direct binding of C/EBPβ to its cognate DNA at position -77 of the
IL6 gene promoter. Strikingly, direct binding of constitutively bound Spi1 to its DNA site at -19
on the IL1B promoter increased significantly under these conditions (Figure 23D), suggesting the
possibility of L-arginine stabilization of Spi1 DNA binding. No enrichment of either C/EBPβ or
Spi1 was observed at the downstream +4858 control site on IL1B. These ChIP studies provide
evidence that the L-arginine-dependent decrease in IL1B mRNA expression is due to its ability to
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inhibit the protein–protein interaction between C/EBPβ and Spi1 on the IL1B gene promoter,
without having any inhibitory effect on either direct DNA binding of C/EBPβ or another C/EBPβdependent gene (IL6).

Figure 23. L-arginine inhibits recruitment of C/EBPb to Spi1 and transcription of the IL1B
gene in living cells. (A) Relative mRNA expression levels for the IL1B gene in THP-1 cells treated
with 1µg/ml LPS for 2.5hr following 12hr pretreatment with indicated concentrations of
L-arginine. (B) Relative mRNA expression levels for the IL1B and IL6 genes in THP-1 cells
titrated with LPS, as indicated, for 2.5hr following the 12hr pretreatment with 10 mM L-arginine.
The mRNA data presented is relative to unstimulated THP-1 cells (vehicle) and was normalized
to cells treated with 1µg/ml LPS for 2.5hr following 12hr pretreatment with 0 mM L-arginine.
ChIP studies on the IL1B gene for (C) C/EBPb and (D) Spi1 in THP-1 cells that are treated with
1µg/ml LPS for 2.5hr following 12hr pretreatment with 10 mM L-arginine. The amplicon -19 on
IL1B gene is Spi1 binding site and +4858 (IL1B) is downstream background control. The amplicon
-77 on IL6 gene is direct C/EBPb binding site. The ChIP data was normalized to amplicon -19 on
IL1B gene in unstimulated THP-1 cells. The primer sequences are indicated in Table 5. The
standard error for all significant samples is representative of at least three biological replicates with
p-value indicated as follows: *p < 0.05 and **p < 0.01.
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3.4. CONCLUSION
Our prior understanding of the mechanism for transcriptional regulation of the human IL1B
gene was based on the realization that its transcription depends on a cell-type-specific transcription
start site promoter and a far-upstream inducible super-enhancer (Shirakawa et al., 1993). This was
followed by the identification of TLR rapid activation of C/EBPβ homo- and hetero-dimer binding
to the enhancer (Tsukada et al., 1994) and constitutive Spi1 binding to the IL1B promoter
(Kominato et al., 1995) as key elements of function. However, it remained unclear how these two
important gene regulatory elements, separated by almost 3 Kbp of DNA sequence might,
mechanistically cooperate. One hint was that the two proteins are capable of a direct interaction
that depends upon the carboxyl terminus of C/EBPβ and the integrity of a single amino acid in the
Spi1 DBD (Listman et al., 2005). Our report of a long-range chromatin loop that positions the
enhancer in close proximity to the promoter prior to gene induction, that rapidly increases in
stability after TLR signaling in human monocytes along with concomitant recruitment of TBP and
Pol II, provided a reasonable mechanistic model (Adamik et al., 2013). What still remained elusive
was the nature of the structural interaction between C/EBPβ and Spi1 and how it contributes to
TBP and Pol II recruitment. Using computational docking, in vitro interaction, and a predicted
inhibitory compound, a reasonable molecular structure is now envisioned for a complex that
anchors the enhancer to the promoter (Figure 24). The interaction is distantly related to that of
C/EBPβ:cMyb in that the C/EBPβ leucine zipper interacts with a DNA-distal surface of the Spi1
wHTH domain by involving the same two chains that bind to cMyb, but is also dependent upon
the entire length of the Chain B tail in order to provide a critical interaction with Arg-232 of Spi1.
Therefore, it is interesting to speculate whether cMyb might support an interaction mode similar
to that of C/EBPβ with Spi1, if it were crystallized with intact tails. This is because a salt bridge
between Glu-336 of C/EBPβ Chain B with Lys-248 of Spi1 in our initial ZDOCK and HADDOCK
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structures, which destabilized early in the NAMD simulation (Figure 18D), is similar to the
reported Glu-336 salt bridge to Arg-114 of cMyb (Tahirov et al., 2002). This suggests that the
C/EBPβ:cMyb structure may be representative of the first stage of a two-step docking mode for
C/EBPβ with Spi1 in which a less stable cMyb-like leucine zipper-only docking provides both an
anchor as well as an increased effective concentration that supports increased collision and
sampling by the Chain B tail. The proximity of the Chain B tail increases the probability of
Arg-232 interaction with the terminal Cysteine 345 of C/EBPb. This interaction may also be
preferred because of the asymmetry of chemical interaction accessibility associated with the Chain
B pocket formed by the Spi1:DNA interaction (Figure 22C). It should also be noted that the
C/EBPβ interaction with cMyb, in contrast to Spi1, includes one direct and one water-mediated
salt bridge with a DNA backbone phosphate, possibly abrogating the requirement for C-terminal
tail interactions.

Figure 24. Four rotational views of the final DNA:C/EBPb:Spi1:DNA composite model.
Showing the locations of the two bZIP chains and the Spi1 wHTH DBD, along with the likely
long-range Enhancer-Promoter DNA interaction, are shown for four 90o rotational views in
association with DNA segments representing the long-range enhancer and promoter sites of the
IL1B gene.
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The presence of the C-terminal tails and the absence of a nucleic acid salt bridge between
C/EBPβ and Spi1 is consistent with the ability of this interaction to be DNA independent during
in vitro GST pulldown experiments, a situation also reported for C/EBPa with GABPa
(Shimokawa et al., 2010; Shimokawa et al., 2013; Shimokawa and Ra, 2005). This also reflects
the conservation between the leucine zippers of C/EBPa and C/EBPβ, as well as the ETS domains
of Spi1 and GABPa (Figure 25).

Figure 25. Homology alignments for (A) C/EBPa and C/EBPβ leucine zippers and
C-terminal tails. The leucine zipper coiled-coil extends to the glutamate residues immediately
preceding the C-terminal tail. Key leucine zipper heptad sites are indicated by black boxes and
sites of direct interaction with wHTH proteins are indicated by arrows. (B) Sequence of C/EBPb
bZIP basic charged DNA-binding sequence and leucine zipper coiled-coil dimerization composite
domain. (C) Schematic representations and homology alignments for the GABPa and Spi1 wHTH
domains. Structural elements are indicated for a-helices and b-sheets.
It is also noteworthy that our data-supported computational model positions the final
C/EBPβ tailed structure on a surface of the 102 amino acid Spi1 DBD that is 180° removed from
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the attachment point of the 170 amino acid Spi1 transactivation domain (TAD) (labeled as K171
in Figure 24). This is important because it places the C/EBPβ docking site in a region that is more
likely to be free of permanent obstruction from the substantial mass of the Spi1 amino terminus.
One might speculate that the TLR4-dependent docking of C/EBPβ might maintain the Spi1 TAD,
which is reported to directly recruit TBP (Hagemeier et al., 1993), in an open conformation
essential for TBP and subsequent Pol II recruitment, consistent with the kinetics associated with
IL1B gene induction (Adamik et al., 2013).
The anti-inflammatory properties of L-arginine are well known (Fritz, 2013). However, the
complexities of L-arginine metabolism have resulted in a vast array of possible targets (Morris,
2016). Our results suggest that L-arginine can block C/EBPβ recruitment by Spi1 at the human
IL1B gene promoter, resulting in decreased TLR4-dependent induction of gene transcription and
suggesting one mode of action for its use as an anti-inflammatory therapeutic. This report deals
with the involvement of L-arginine in a specific transcription mechanism and suggests one possible
target that may serve as a model for the design of a novel and specific pro-inflammatory gene
inhibitor. The central involvement of IL-1β protein in numerous pro-inflammatory acute diseases
and cancer has underscored the importance of antibody therapy (Everett et al., 2018; Ridker et al.,
2017). However, antibody therapy targets the huge number of IL-1β protein molecules that are
derived from IL1B gene transcription in each activated cell. Blocking transcription provides an
upstream target that precedes the amplified “storm” of IL-1β protein expression and can
theoretically provide a much more effective method for inhibition. Of course, such inhibition
requires both a reasonable efficiency for cell permeation as well as high specificity for a target.
Unfortunately, virtually all protein-coding genes use a common promoter transcription initiation
mechanism and most transcription factors function as pleiotropic enhancer–binding proteins with
broad gene activity that obviates therapies that depend on either direct promoter inhibition or
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specific enhancer DNA binding. This is certainly the case for Spi1, which predominantly functions
as an enhancer–binding factor. Our observation that the human IL1B gene promoter utilizes a
unique protein–protein interaction at a core promoter that can be selectively targeted and repressed,
offers the potential for a correspondingly novel therapeutic mode targeting protein–protein, rather
than protein–DNA, interaction within the cell. It also begs the question whether there are other
genes that are similarly regulated either by Spi1 or by other transcription factors that function both
as enhancer-dependent activators, as well as core promoter general transcription factors.
Regardless, our results demonstrate that at least one gene can be selectively repressed by inhibition
of protein–protein interaction at a core promoter.

3.5. MATERIALS AND METHODS
3.5.1. Cell Culture, Reagents and Treatment Conditions
THP-1 cell line (ATCC, TIB-202) was initially cultured in RPMI-1640 media (Corning,
10-040-CV) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, SH30070.03),
1% Penicillin/Streptomycin Solution (Corning, 30-002-Cl) and 500 μl of 2-mercaptoethanol
(Gibco, 21985023). RPMI-1640 media lacking amino acid L-leucine, L-lysine and L-arginine was
purchased from Sigma, R1780. This media was supplemented with 50mg/L of L-leucine (Sigma,
L8912) and 40mg/L of L-lysine monohydrochloride (Sigma, L8662), which is same amount of
these amino acids in classic RPMI-1640 media but without L-arginine. It was also supplemented
with

10%

heat-inactivated

fetal

bovine

serum

(Hyclone,

SH30070.03),

1%

Penicillin/Streptomycin Solution (Corning, 30-002-Cl) and 500 μl of 2-mercaptoethanol (Gibco,
21985023). For mRNA and ChIP analyses, the THP-1 cells grown in classic RPMI-1640 media
were washed and transferred into RPMI-1640 media lacking L-arginine. These cells were pre-
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treated with different concentrations of L-arginine (Sigma, A8094) for 12 hours prior to E. coli
055:B5 Lipopolysaccharide (LPS) (L2880, Sigma) stimulation for 2.5 hours.

3.5.2. Small Molecule Docking with MOE
Two potential binding pockets proximal to our amino acid residue of interest, Arg-232, on
opposite sides of DNA-bound Spi1 from RCSB 1PUE (Berman et al., 2000; Kodandapani et al.,
1996) (resolution: 2.1 Å; R-value free: 0.287; R-value work: 0.225) were identified with Molecular
Operating Environment’s (MOE) SiteFinder (Edelsbrunner, 1992; Edelsbrunner et al., 1995).
Conformations of small molecule drugs (78-180g/mol) from DrugBank (Law et al., 2014) were
docked to both pockets using MOE’s Amber10:EHT (Extended Hückel Theory parameterization)
force field (Gerber and Muller, 1995) and induced fit docking protocol, which relaxes the structure
as it docks. The potential binding sites were identified using dummy atoms defining the binding
pockets, potential poses were determined via the Alpha Triangle match method, and initially the
poses were scored with the Affinity dG method. Each pose and the pocket atoms (residues greater
than 6 Ångstroms from the pocket are not included in the energy minimization or the energy
evaluation; backbone atoms are held fixed) were energy minimized using the Generalized Born
solvation model (GB/VI) (Wojciechowski and Lesyng, 2004). After energy minimization, the
poses are rescored with the GBVI/WSA dG method. Top ranked compounds with established links
to IL-1B or inflammation in literature were selected as compounds of interest.

3.5.3. Protein–Protein Docking
The protein–protein docking of the Spi1:C/EBPβ DNA-bound complex used the murine
Spi1 and human C/EBPβ structures found in RCSB entries 1PUE (Kodandapani et al., 1996) and
1H88 (Tahirov et al., 2002) (resolution: 2.8 Å; R-value free: 0.277; R-value work: 0.222),

70

respectively. A series of docking runs was performed using the ZDOCK server (Pierce et al., 2014),
using a fast Fourier transform-based docking algorithm that takes into account pairwise shape
complementarity, desolvation, electrostatics, and statistical potential. When both proteins were
DNA-unbound and also when Spi1 was DNA-bound and C/EBPβ unbound with its bZIP marked
as passive at residues 315 and below, ZDOCK results reliably indicated that the C/EBPβ bZIP
domain associates with the Spi1 β-turn domain in an orientation notably not proximal to the residue
of interest, Arg-232.
To reinforce the results from ZDOCK, additional docking was performed using the
HADDOCK webserver (Dominguez et al., 2003; van Zundert et al., 2016), which incorporates
biochemical interaction data to drive docking. The Easy Interface was used with active (involved
in contact) and passive (solvent accessible neighbors) residues entered based on previous
experimental data. For Spi1 (des-DNA), actives were 243, 245-254 (β3/β4 strands and loop) and
passives were 171-219 (α helices not in contact with DNA and β1/β2 strands and loop). On
C/EBPβ, the dimer chains were combined into one and the residues of one chain were renumbered,
with active 330-336 and passive 276-293. Again, results showed the C/EBPβ bZIP domain docked
to the Spi1 β turn domain in the same orientation.
Because C/EBPβ did not dock particularly close to Spi1 Arg-232, it was suggested that the
disordered 9-residue C-terminus end strands, which are not found in the C/EBPβ 1H88 crystal
structure, could be associating with Arg-232 on one or both sides of the complex. The strands were
appended to the docked protein–protein structure on both chains of C/EBPβ and LowModeMD
(Labute, 2010), a dynamics simulation method to predict the orientation of protein loops, was used
to wrap the strands around to each pocket, creating an approximate model of the proposed
interaction.
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3.5.4. mRNA Expression Analysis
1x106 THP-1 cells in RPMI-1640 media lacking L-arginine were plated into 6-well plates
(Thermo Fisher BioLite, 130184). Following the L-arginine and LPS treatments, cells were
pelleted and supernatant was removed. The cell pellet was re-suspended in 500 μl of TRIzol
reagent (Invitrogen, 15596026). Following the addition of 170 μl of Chloroform (Fisher, C606-1),
the samples were vortexed well and incubated at room temperature for 15 minutes. Then, the
samples were centrifuged at 13200 RPM for 15 minutes at 4oC. Aqueous layer was transferred into
a fresh tube and combined with 500 μl of isopropanol (Fisher, BP2632-4) and 1 μl of Glycogen
(Ambion, AM9510). The samples were incubated at room temperature for 10 minutes and then
centrifuged at 13200 RPM for 10 minutes at 4oC. The RNA pellets were washed with 500 μl of
75% Ethanol (Pharmaco-AAPER, 111ACS200) and centrifuged for 10 min in room temperature
at 14000 RPM. Then, the ethanol was aspirated, and the pellets were allowed to air-dry for 10-15
minutes. Air-dried pellets were re-suspended in 25 μl of DEPC-treated water (Ambion, AM9920).
The samples were incubated at 65oC for 10 minutes and subjected to DNase treatments using Turbo
DNA-free reagents (Ambion, AM1907) according to the manufacturer instructions in order to
eliminate genomic DNA contamination. RNA concentration, 260/280 and 260/230 values were
measured using NanoDrop 1000 spectrophotometer (Thermo Fisher, ND-1000). mRNA was
converted into cDNA using GoScript Reverse Transcription System (Promega, A5001). cDNA
was analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus Applied Biosystems
Real Time Instrument (Thermo Fisher, 4376600). Relative expression levels were calculated using
DDCt method with GAPDH (Reference gene) and unstimulated THP-1 cells as a control. Primer
Sequences used for mRNA analysis are indicated in Table 4.
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Gene

Forward Primer

Reverse Primer

IL1B

TCCAGGGACAGGATATGGAG

TCTTTCAACACGCAGGACAG

IL6

AGGAGACTTGCCTGGTGAAA

CAGGGGTGGTTATTGCATCT

GAPDH

ACACCCACTCCTCCACCTTT

CCCTGTTGCTGTAGCCAAAT

Table 4. qPCR primer sequences for mRNA analysis. Table shows the forward and reverse
primer sequences used for mRNA analysis.
3.5.5. Chromatin Immuno-precipitation
ChIP was performed using a modification of the Millipore/Upstate protocol
(MCPROTO407). Following treatments, a total of 1x107 THP-1 monocytes in RPMI-1640 media
lacking L-arginine were fixed in 1% formaldehyde (Fisher, F79-500) for 10 min at room
temperature. Cross-linking was inhibited by addition of glycine (Fisher, G46-1) to a final
concentration 0.125 M. Cell pellets were washed twice with ice cold PBS and resuspended in SDS
Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) supplemented with Protease inhibitor
cocktail (Sigma, P8340) and 1mM phenylmethylsulfonyl fluoride (Sigma, 93482). Samples were
sonicated (to generate DNA fragments of 250 base pairs (bp) average length) on ice using a Fisher
Scientific 120 Sonic Dismembrator (Fisher Scientific, FB-120) as follows: 30 seconds ON and 30
seconds OFF at 50% amplitude for 12 cycles on ice and centrifuged at 12000 RPM for 10 min.
Chromatin was diluted 7-fold in ChIP Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-HCl, pH8.1, 167 mM NaCl. Total equivalence of 3x106 cells was used for
both C/EBPb and Spi1 pull downs. Supernatants were incubated at 4°C overnight with Santa Cruz
antibodies C/EBPb (sc-150X, sc-56637), Spi1 (sc-352X, sc-22805X) and control IgG (sc-2027X).
For the C/EBPb pull downs, both the sc-150X and sc-56637 antibodies were mixed in equal
amounts. Similarly, for the Spi1 pull downs sc-352X and sc-22805X were mixed. Aliquots for
Input and non-specific IgG control samples were included with each experiment. Samples were
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precipitated using 25 µl of Magna ChIP Protein A+G Magnetic beads (EMD Millipore, 16-663),
at 4°C for 3 hours, and subsequently washed with the following solutions: once with Low-Salt
Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl),
once with High-Salt Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1,
550 mM NaCl), once with LiCl Wash Buffer (0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic
acid, 1mM EDTA, 10 mM Tris, pH 8.1), and twice with TE Buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8.0). Immunocomplexes were eluted for 4 hours at 65°C with 200 µl of ChIP Elution Buffer
(1% SDS, 0.1M NaHCO3). To reverse the cross-linking, eluted samples were treated with 10 µl of
5 M NaCl and subsequently incubated at 65°C for ≥4 hours. DNA was purified using a GeneJET
PCR Purification kit (Thermo Scientific, K0702). Primer Sequences used for ChIP analysis are
indicated in Table 5. The size of the PCR products ranges between 80 and 150 bp. 20 μl qPCR
reactions containing 2x Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific,
K0223), 250 nM of primers, and 3 µl of precipitated DNA were set up in Fast 96-Well Reaction
Plates (Applied Biosystems, 4346907). qPCR reactions were carried out in a StepOnePlus Applied
Biosystems Real Time Instrument (Thermo Fisher, 4376600). Fold enrichment was calculated
based on Ct as 2(DCt), where DCt = (CtInput - CtIP). Final enrichment values were adjusted by
subtraction of the nonspecific IgG antibody binding.

Position

Forward Primer

Reverse Primer

-77 IL6

TGCACTTTTCCCCCTAGTTG

TCATGGGAAAATCCCACATT

-19 IL1B ACAACTAGGTGCTAAGGGAGTC AGGAGAGGGAGAGACAGAGAAAGA
+4858
IL1B

AGTAGCCAAAGCCTCTGCAC

CCGATTCCAAAGAAACAGGA

Table 5. Human IL6 and IL1B ChIP primer sequences. Primer sequences used for ChIP
analysis. The numbers indicate the midpoint of amplicons in relation to the transcription start site.
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3.5.6. In vitro studies
The C/EBPβ pCDNA3.1 (Tsukada et al., 1994), Spi1 pRC/CMV (Galson et al., 1993) and
Spi1 deletion (Wara-aswapati et al., 1999) expression vectors were constructed as previously
described. All constructs were verified by DNA sequencing. Purification of fusion proteins and
DNA-independent glutathione-S-transferase (GST) pull-down assays were as we described
previously (Listman et al., 2005). This approach was used because DNA-independent Spi1
protein–protein interactions correlate with Spi1-dependent gene regulation (Adamik et al., 2013;
Listman et al., 2005; Meraro et al., 1999; Nagulapalli et al., 1995; Perkel and Atchison, 1998;
Wara-aswapati et al., 1999; Yang et al., 2000).

3.5.7. Nanoscale Molecular Dynamics (NAMD)
I. System Preparation
The Spi1-C/EBPb-DNA system used in the MD simulations was constructed from two
published crystal structures. The binary C/EBPb-DNA portion of the system was taken from the
ternary complex in RCSB 1H89 (Tahirov et al., 2002) (resolution: 2.45 Å; R-value free: 0.267; Rvalue work: 0.229). A second crystal structure, RCSB 1PUE, was used for the Spi1 structure
(Kodandapani et al., 1996). Using sequences for C/EBPb gathered from the Uniprot (The UniProt,
2017) entry for human CEBPb, tails were added to the non-interacting C-termini of the binary
C/EBPb-DNA structure in 1H89. These tails enable enhanced binding of C/EBPb to the Spi1DNA complex. This system was prepared from the two crystal structures and the aforementioned
tail sequences using Visual Molecular Dynamics (VMD) (Humphery et al., 1996). The tails were
attached to the termini of both chains of C/EBPb using the psfgen module in VMD. A 76×70×150
Å solvation box contained 22,623 water molecules was placed around the protein–DNA complex
using the Solvate package of VMD; no additional molecules were added to the system.
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II. Simulation Details
The NAMD software package (Phillips et al., 2005) was used to perform MD simulations
on the Spi1:C/EBPb-DNA complex. The CHARMM36 force field (Huang and MacKerell, 2013)
was used for all simulations to assign atomic partial charges, calculate forces, and potential
energies. Constant volume, temperature, and number of atoms (NVT) were maintained during the
preliminary equilibration simulations, and volume was allowed to vary while pressure was held
constant (NPT) during the final equilibration run and data production simulations. All simulations
were carried out at 300 K, and 1.01325 atm was maintained during NPT simulations. The velocity
Verlet algorithm was used for MD integration with a 1 fs timestep. For nonbonded interactions,
pair lists were maintained for pair distances less than 12 Å with an interaction cutoff distance of
10 Å, and a switching function was applied at a distance of 8 Å. All positional constraints
mentioned below were held with a 0.5 kcal Å-1 mol-1 force constant. Full system electrostatics was
calculated with the particle mesh Ewald summation (Darden et al., 1993) method. The TIP3P water
model (Jorgensen et al., 1983) was used for explicit water solvation, and cubic periodic boundary
conditions were utilized. A Langevin thermostat and piston were used to maintain constant
temperature and pressure respectively.

III. MD Simulations.
Conjugate gradient minimization was performed for 5000 steps with positional constraints
placed on protein/DNA heavy atoms, followed by 5000 more steps of minimization without
constraints. An NVT equilibration (Jorgensen et al., 1983) was then performed for 2 ns with
position of the protein/DNA backbone heavy atoms constrained, and 2 ns with these constraints
removed to enable the solvent to relax before the larger molecules. Throughout all the simulations
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carried out, positional constraints were maintained on the terminal residues of the DNA chains, to
disable the system from shifting in a manner than would disrupt the periodic boundary conditions.
Otherwise, DNA chains were allowed to freely move. Following the NVT equilibration, NPT
equilibration was carried out for 5 ns with no additional constraints. 104 ns of data production MD
simulation was performed under the NPT ensemble, with trajectory and observable data being
recorded at 2 ps intervals.

IV. Data Analysis
All data analysis was performed with VMD. Inter-atomic distance time traces for the
various residue pairs discussed in this work were calculated each step from the DCD trajectory
with Tcl analysis scripts. Buried surface areas discussed in this work were calculated for each
frame of the MD trajectory by subtracting the solvent accessible surface areas (SASA) for the
individual protein chains from the SASA of the complex, which is a commonly used method to
calculate this metric. Mathematically, an example of this protocol to calculate the buried surface
area of complex ABC is given as:

)
*
+
)*+
𝑆𝐴)*+
#$%&'( = (𝑆𝐴𝑆𝐴 + 𝑆𝐴𝑆𝐴 + 𝑆𝐴𝑆𝐴 ) − 𝑆𝐴𝑆𝐴

1
where 𝑆𝐴)*+
#$%&'( is the buried surface area for the complex ABC and 𝑆𝐴𝑆𝐴 is the solvent

accessible surface area for chain N. Buried surface area calculations were carried out using Tcl
scripts in VMD.
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Chapter 4: Molecular Insights into IL1B gene
regulation
This Chapter contains a series of preliminary studies that either require more supporting
experiments to derive a conclusion or more experimental/biological replicates before consideration
for publication.
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4.1. ABSTRACT
Interleukin 1b (IL-1b) and Tumor Necrosis Factor (TNF) are important mediators of
inflammatory responses and intracellular communication in the body against microbial infection.
To understand the transcriptional kinetics of these pro-inflammatory cytokines, the mRNA kinetic
profile in THP-1 monocytes following LPS or Phorbol 12-Myristate 13-Acetate (PMA)
stimulation was analyzed. The IL1B and TNF genes showed distinct mRNA profiles with LPS
and/or PMA stimulation. Following LPS stimulation, the TNF gene was rapidly induced with an
absence of expression in the late phase, while refractory to LPS re-stimulation. The IL1B gene
showed a rapid-vigorous induction, followed by a decreased continuous expression, which can be
re-induced with LPS stimulation. In contrast to LPS, PMA generated a lower-level of sustained
IL1B expression in the late phase, with only a minute induction of TNF. Furthermore, the addition
of both LPS and PMA together revealed super-induction of the IL1B gene in the late phase,
indicating the synergistic effect of LPS and PMA. The addition of PMA to LPS-activated THP-1
cells did not show any significant induction of the TNF gene. ChIP analysis revealed that in
TLR4-activated monocytes, NF-κB is necessary for both the initial and continuous, late,
expression of the IL1B gene, with C/EBPβ being important only for the rapid initial expression.
TNF gene expression was mostly dependent on NF-κB, with minimal involvement of C/EBPβ.
Late phase expression of the IL1B gene with PMA was dependent on both NF-κB and C/EBPβ.
Super-induction of the IL1B gene with LPS+PMA was associated with continuous strong binding
of both NF-κB and C/EBPβ to the IL1B promoter and enhancer. Our preliminary studies have
shown that extracellular succinate, likely acting through the SUCNR1/GCPR91 receptor, can
potentially enhance LPS induced re-stimulation of the IL1B gene. The Spi1 transcription factor is
constitutively expressed and absolutely necessary for IL1B gene transcription in monocytes. Using
luciferase reporter assays and mRNA expression studies, we have shown that serine
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phosphorylation in both the Transcription Activation Domain (TAD) and PEST phosphorylation
target domain of Spi1 play an important role in the LPS-dependent activation of Spi1. These
preliminary studies provide new molecular insights into IL1B gene regulation in TLR4-activated
monocytes.

4.2. INTRODUCTION
Innate immune cells are the first cellular components of the immune system that comes
into contact with invading pathogens. A number of innate immune genes are required to rapidly
respond (Immediate Early Genes) to a wide variety of external stimuli from pathogenic microbes.
Immediate Early (IE) genes are rapidly transcribed within minutes following stimuli independent
of de novo protein synthesis (Bahrami and Drablos, 2016). It is widely believed that all IE rapidly
induced genes depend upon paused RNA Polymerase II (Pol II) located at 50 bp downstream the
TSS before the appropriate stimuli release the paused Pol II to start active transcription (Adelman
et al., 2009; Jonkers and Lis, 2015; Liu et al., 2015). Classical IE genes like TNF and FOS have
pre-bound TBP and Pol II at their respective promoters prior to gene induction (Adamik et al.,
2013; Ryser et al., 2007). These IE genes have many canonical core promoter elements like
Initiator (Inr), Downstream Promoter Element (DPE) and Downstream Core Element (DCE)
sequences that recruit TFIID and the RNA Polymerase II Pre-Initiation Complex (PIC) to the
promoter site. However, recent studies have shown that not all IE genes have paused Pol II and
pre-bound TBP at the promoter prior to gene induction (Adamik et al., 2013; Gupte et al., 2013).
Unlike classical IE genes, the IL1B gene promoter does not possess canonical core promoter
elements and is devoid of pre-bound TBP and Pol II but has a constitutively bound myeloid
lineage-specifying Spi1 transcription factor. Previous studies have demonstrated that Spi1 is
absolutely necessary for IL1B gene transcription in TLR4-activated monocytes (Adamik et al.,
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2013; Kominato et al., 1995; Tsukada et al., 1997; Unlu et al., 2007). The Spi1 binding site is
immediately adjacent to the TBP binding site on the IL1B gene promoter, and it has been reported
that Spi1 can directly recruit TBP via its amino-terminal transactivation domain (Hagemeier et al.,
1993). Previous studies have also reported that the IL1B gene has a decreased, prolonged,
expression after the initial TLR4-activation, and can be re-induced with secondary activation
(Adamik et al., 2013). This contrasts the TNF gene, which is both completely shut-down after
initial rapid induction and is refractory to re-stimulation (Adamik et al., 2013). Therefore, to
understand the distinct molecular mechanism regulating the IL1B gene, as compared to TNF, the
transcription factors responsible for the IL1B and TNF gene kinetics were examined. The roles
played by extracellular succinate in the re-stimulation phase of the IL1B gene and LPS-dependent
serine phosphorylation of Spi1 to prime IL1B gene induction were also investigated. The studies
included in this chapter, exploring the molecular mechanisms of IL1B gene expression, are
preliminary, requiring either additional supporting experiments or biological replicates.

4.3. RESULTS AND DISCUSSION
4.3.1. The IL1B gene exhibits sustained expression in TLR4-activated monocytes
To understand the IL1B and TNF gene activation kinetics, we took advantage of the short
half-lives of these messages (Brooks et al., 2004; Fenton et al., 1988) by using mRNA levels as a
readout for gene transcription. Distinct mRNA expression profiles were observed for IL1B and
TNF, when the THP-1 monocytes were stimulated with LPS, PMA (Phorbol 12-Myristate 13Acetate), or LPS+PMA at various time points over 24 hours. Unlike, LPS which is present on
outer bacterial membranes and activates TLR4 receptors on monocytes, PMA mimics
Diacylglycerol which activates Protein Kinase C, resulting in a downstream signaling cascade
(Castagna et al., 1982; Traore et al., 2005). With LPS treatment alone (shown in green in Figure
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26A), IL1B showed two distinct phases: an IE rapid-vigorous phase followed by a decreased
continuous expression. In contrast, TNF showed only a rapid-transient IE induction followed by a
complete shut-down at the later stage. PMA treatment (shown in blue in Figure 26A) resulted in a
delayed, but sustained, lower level of expression for IL1B, with only a minute effect on TNF. The
addition of both LPS+PMA together (shown in brown in Figure 26A) resulted in super-induction
of IL1B gene expression, only displaying a curve for TNF that was similar to that of LPS,
demonstrating once again that PMA has only a minimal effect on TNF expression. These mRNA
results support and expand on previous studies showing that IL1B and TNF have distinct gene
activation kinetics. The sustained expression of the IL1B gene is associated with many
auto-inflammatory diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease,
asthma along with heart disease, cancer, Alzheimer’s disease and diabetes (Braddock and Quinn,
2004). Understanding the molecular mechanisms that contribute to this sustained expression of the
IL1B gene might provide insights into developing new therapeutic approaches to tackle diseases
that are caused by chronic expression of IL-1b.

Figure 26. IL1B and TNF have distinct mRNA expression profiles. A) Shows the relative
mRNA expression levels of the IL1B and TNF genes in THP-1 cells stimulated with LPS, PMA,
and LPS+PMA for various times over 24 hours. Error bars represent three biological replicates.
B.) Composite figure showing the morphological changes in THP-1 monocytes once stimulated
with either LPS or PMA or LPS+PMA for 24 hours.
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LPS and PMA treatments also resulted in morphological changes in THP-1 cells over 24
hours (Figure 26B). Unstimulated cells remained round in shape and barely attached to the surface
of the plate. LPS stimulated cells acquired ruffled edges and adhered to the plate. PMA stimulated
cells showed strong adherence to the surface of the plate, with some cells becoming polarized and
macrophage-like at 24 hours. The addition of both LPS+PMA to THP-1 cells also generated strong
attachment to the plate, along with a higher percentage of polarized macrophage-like cells. These
results nicely agree with many previous studies revealing that LPS increases the expression of cell
adhesion molecules (CAMs) such as ICAM-1, V-CAM-1 and E-selectin, whereas PMA
upregulates P-selectin, LFA-1 and ICAM-1 facilitating monocyte/macrophages cell adherence
(Sellak et al., 1994; Takamatsu, 2018). CAM upregulation upon activation is essential for
adherence of monocytes to endothelial cells and transmigration to sites of infection/inflammation
(Hmama et al., 1999). LPS and PMA treatments are also known to support actin cytoskeleton
reorganization that alters the morphology of monocytes upon activation (Takamatsu, 2018;
Williams and Ridley, 2000).

4.3.2. NF-κB and C/EBPβ are both required for IL1B gene expression in TLR-4 activated
monocytes
To identify the roles of NF-κB and C/EBPβ in IL1B and TNF gene expression, we
performed a screen using relatively specific transcription factor inhibitors (BMS: IKK inhibitor
for NF-κB and U0126: C/EBPβ p38 MAPK inhibitor) for immediate-early (IE) and late phases of
gene expression. THP-1 cells treated with LPS and specific transcription factor inhibitors
demonstrated that the rapid-vigorous IE expression and continuous late expression of IL1B
depended upon both NF-κB and C/EBPβ (Figure 27). In contrast, TNF early phase IE expression
appeared to be almost exclusively dependent on NF-κB, with minimal involvement of C/EBPβ
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(Figure 27). The relative mRNA expression studies for THP-1 cells treated with PMA and specific
transcription factor inhibitors revealed that the lower-level early expression, as well as sustained
late expression for IL1B, was dependent on both NF-κB and C/EBPβ (Figure 27). The TNF gene
did not show any significant expression with PMA treatment. Finally, when the cells were treated
with both LPS+PMA, along with specific transcription factor inhibitors, the early and the late
phase IL1B gene expression was dependent on both NF-κB and C/EBPβ (Figure 27). In contrast,
the early phase expression of the TNF gene with both LPS+PMA treatment was mostly dependent
on NF-κB with only a minimal involvement of C/EBPβ (Figure 27).
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Figure 27. Expression of IL1B and TNF genes is dependent on both NF-κB and C/EBPβ. The
figure shows IL1B and TNF mRNA expression kinetics in THP-1 cells treated with either LPS,
PMA or LPS+PMA, along with specific transcription factor inhibitors (BMS: IKK inhibitors for
NF-κB; U0126: C/EBPβ p38 MAPK inhibitor) in immediate-early (IE) and late phases of gene
expression. Error bars represent two biological replicates.
Next, to directly verify the involvement of these transcription factors, Chromatin
Immunoprecipitation (ChIP) was conducted in early (1.5hr) and late (7hr) phase treatments. A
significant enrichment of NF-κB was observed after 1.5hr of LPS stimulation, both at the
mini-enhancer NF-κB (-279) and Spi1 binding sites (-91) at the IL1B gene promoter, as compared
to a downstream control (+4858) (Figure 28). At 7 hours, there was decreased NF-κB binding at
both sites, as compared to 1.5 hours, but still demonstrated a significant enrichment over the
downstream control (Figure 28). Consistent with the inhibitor data, these ChIP results indicate that
NF-κB is required for both early and decreased late expression of the IL1B gene in TLR4-activated
monocytes. When LPS binds to the TLR4 receptor, it activates NF-κB through the recruitment of
an adaptor protein, Myeloid Differentiation Primary Response Gene 88 (MyD88). The initial
activation of NF-κB through MyD88 is very rapid, and an increased NF-κB binding on the IL1B
promoter can be observed as early as 30 minutes post TLR-4 activation by LPS (Adamik et al.,
2013). Recent studies have shown that LPS activation of TLR4 can induce NF-κB in the late phase
via TIR-domain-containing adapter-inducing interferon-b (TRIF)-mediated signal transduction
(Cheng et al., 2015; Tan et al., 2015). After the initial activation of the TLR4 receptor, CD14 has
been shown to mediate the internalization of TLR4 into endosomes (Zanoni et al., 2011). Once the
TLR4 receptor is recruited into endosomes, the internalized receptor engages the TRIF adaptor
which is known to activate NF-κB. Since the activation of the TRIF pathway by TLR4 is late
compared to rapid MyD88 activation, it would be interesting to inhibit TRIF signaling in
LPS-activated monocytes and analyze the IL1B mRNA kinetic profile. If the TRIF signaling
pathway is important only for the late activation of NF-κB, a decreased IL1B mRNA expression
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would be observed in the late phase with TRIF inhibitor, and the resulting IL1B mRNA profile
should look more like TNF, with only an initial peak and minimal late phase gene expression.
These inhibitor studies can be followed-up with NF-κB ChIP assays on the IL1B gene in
LPS-activated monocytes with TRIF inhibitor.

Figure 28. Late phase super-induction of the IL1B gene with LPS+PMA requires continuous
binding of both NF-κB and C/EBPβ. The figure shows NF-κB and C/EBPβ ChIP results for the
THP-1 cells stimulated with either LPS, PMA or LPS+PMA in immediate-early (IE) and late
phases of IL1B gene expression. Error bars represent two biological replicates.
C/EBPβ binding was observed only at the early phase (1.5hr) of LPS stimulation at both
the IL1B promoter (-155, -91) and UIS enhancer (-2790) regions (Figure 28). Consistent with
PMA-induced IL1B mRNA expression, a weak but significant enrichment of NF-κB at both the
promoter (-91) and mini enhancer site (-279) was observed only in the late induction phase.
Similarly, C/EBPβ enrichment following PMA treatment was also observed only in the late phase,
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both at the promoter and UIS enhancer sites on IL1B. These results indicate that in the case of
PMA activation, both NF-κB and C/EBPβ contribute to the delayed, sustained IL1B gene
expression. As indicated by the inhibitory mRNA studies, LPS+PMA treatment showed
enrichment for both NF-κB and C/EBPβ in the early and late phases at their respective binding
sites (Figure 28). These LPS+PMA ChIP results suggest that the super-induction of the IL1B gene
might be due to strong continuous binding of both the NF-κB and C/EBPβ transcription factors.

Figure 29. Both NF-κB and C/EBPβ effect TNF gene expression. The figure shows NF-κB and
C/EBPβ ChIP results for the THP-1 cells stimulated with either LPS, PMA or LPS+PMA in early
(IE) and late phases of TNF expression. Error bars represent two biological replicates.
In the case of TNF, significant binding of NF-κB was observed at the enhancer NF-κB site
(-600) as compared to the promoter site (-128) after 1.5hr of LPS stimulation (Figure 29).
Decreased NF-κB binding was observed at the later 7hr time point, even though there was no TNF
expression in the late phase. Previous studies from our laboratory have shown that the +1
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nucleosome on the TNF gene is re-deposited by 5-hours (late phase) after the initial TLR4
activation thereby impeding TNF gene expression (Adamik et al., 2013). But in the case of the
IL1B gene, the nucleosome binding at the +1 position remained low in the late phase accompanied
by active gene transcription. The exact molecular mechanism contributing to the increased +1
nucleosome enrichment at the TNF promoter is unknown. C/EBPβ binding to the TNF promoter
site (-128) was observed only in the early phase of LPS stimulation (Figure 29). Consistent with
TNF mRNA expression profile, NF-κB binding was not observed on the TNF gene following PMA
treatment (Figure 29). Interestingly, a slight enrichment of C/EBPβ was observed at the TNF
promoter site (-128) in the late phase with PMA treatment. Finally, NF-κB enrichment on the TNF
gene with LPS+PMA treatment was very similar to the LPS only treatment, with significant NF-κB
binding in the early phase at the enhancer site, along with a decreased binding in the later phase.
Both in the early and late phase of LPS+PMA treatment, C/EBPβ was enriched at the TNF
promoter site (Figure 29). These results, along with the inhibitory studies, argue that C/EBPβ has
a minor effect on TNF gene expression.

4.3.3. Extracellular succinate supports LPS induction of IL1B gene expression
Previous studies from our lab have shown that the IL1B gene, unlike that of TNF, is less
sensitive to endotoxin tolerance (re-induction) and can be re-activated upon secondary LPS
stimulation (Adamik et al., 2013). Consequently, kinetic mRNA studies were performed in order
to compare the expression of IL1B with the endotoxin tolerant TNF gene, following secondary
stimulation (2o) of THP-1 cells with LPS. Therefore, THP-1 cells were first treated for 24 hours
with LPS, followed by re-stimulation with the same LPS dose for various time points over 24
hours, without washing the cells between stimulation treatments. These studies revealed that the
IL1B mRNA expression profile for re-stimulation was similar to the initial LPS profile, with a

88

rapid transient expression, followed by a sustained decreased expression (Figure 30). In contrast,
the TNF gene revealed a much lower level of absolute re-stimulation with secondary LPS treatment,
as compared to the IL1B gene.

Figure 30. LPS re-stimulation profile for IL1B is similar to that of primary LPS treatment.
The figure shows IL1B and TNF mRNA expression profiles with LPS-only stimulation (1o) in blue
and LPS re-stimulation (2o) in red for the indicated time points. Error bars represent two technical
replicates for LPS-only treatment and two biological replicates for LPS re-stimulation samples.
Succinate, an intermediate metabolite in the Tricarboxylic acid cycle is well established as
an important onco-metabolite that drives the Warburg effect in cancer cells (Selak et al., 2005).
However, recent studies have shown that succinate also plays an important role in inflammation
through the upregulation of the pro-inflammatory cytokine, IL-1β, in LPS-stimulated macrophages
(Mills et al., 2016; Tannahill et al., 2013). Activated macrophages can upregulate the expression
of extracellular succinate receptor SUCNR1/GPCR91 and secrete succinate which can act in an
autocrine and paracrine manner to stimulate the SUCNR1 receptor on macrophages to increase
proIL-1β expression (Littlewood-Evans et al., 2016; Rubic-Schneider et al., 2017; van Diepen et
al., 2017). Since, previous studies have demonstrated that washing the cells prior to secondary LPS
challenge decreases the re-stimulation of the IL1B gene (Adamik et al., 2013), we hypothesized
that the wash step removes extracellular succinate in the media that might be necessary for
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secondary stimulation of the IL1B gene. After the initial LPS stimulation, THP-1 cells were
subjected to secondary LPS challenge with or without washing the cells with serum-free
RPMI-1640 in the presence or absence of extracellular succinate. Washing the cells prior to
re-stimulation decreased the IL1B gene expression but did not completely negate the IL1B gene
response to re-stimulation (Figure 31). The addition of extracellular succinate along with a
secondary LPS dose, following the wash step, slightly increased IL1B gene expression, when
compared to the same treatment without extracellular succinate. These preliminary trend data
suggest that washing the cells prior to secondary stimulation may remove the extracellular
succinate which might otherwise support LPS induction of the IL1B gene in monocytes. However,
additional biological replicates and supporting experiments are required to provide conclusive
evidence that extracellular succinate plays a role in LPS re-stimulation of the IL1B gene. It should
be noted that these studies were conducted with a very high concentration of LPS (1 µg/ml). The
co-operative effect of extracellular succinate on IL1B gene expression may be more striking if the
same experiment were repeated with a lower concentration of LPS (10 ng/ml or 20 ng/ml).
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Figure 31. Extracellular Succinate supports LPS re-stimulation of IL1B. The figure shows the
effect of extracellular succinate on IL1B in LPS-treated THP-1 monocytes. Error bars represent
two biological replicates.
4.3.4. LPS dependent serine phosphorylation is required for Spi1 transcription factor
activation of the IL1B gene promoter
Previous studies have demonstrated that LPS activates casein kinase II, which in turn
phosphorylates serine residues on the Spi1 transcription factor (Lodie et al., 1997). We
hypothesized that this phosphorylation event for pre-bound Spi1 may be required for its activation
of IL1B gene transcription in TLR-4 activated monocytes. To test this hypothesis, the luciferase
reporter assay with the IL1B XT-Luc expression vector was performed on various Spi1 point
mutants and deletions in HEK293T cells. HEK293T cells do not express TLR4 receptor, but can
transcribe the IL1B gene when TRAF6, IRF8 and wild-type Spi1 are ectopically expressed, which
our group previously demonstrated (Adamik et al., 2013; Wang et al., 2006). Figure 32A shows
the schematic of Spi1 domains with various known serine phosphorylation sites that were mutated
to alanine (Celada et al., 1996). The Serine to Alanine point mutants in the TAD domain (S41A,
S45A and S41A+S45A) and the PEST domain (S148A) showed a significant decrease (about 60%)
in luciferase activity (Figure 32B). The PEST domain deletion also showed similar levels of
luciferase activity as the point mutants. The D1-100 (TAD) and D8-29 (TBP binding region)
domain deletions were used as negative controls. No significant activity was detected in these
deletions over the background. These luciferase assay results suggest that serine phosphorylation
of both the TAD and PEST domains play a significant role in Spi1 activation. In order to validate
the luciferase assay results, the IL1B mRNA expression levels were analyzed using the same
expression vectors as the luciferase reporter studies, with the exception of the XT-Luc vector, in
HEK293 cells. These mRNA studies reveal a 1000 to 2500-fold decrease in IL1B gene
transcription with the Spi1 point mutants, as compared to the Wild-type Spi1 (Figure 32C). The
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S148A Spi1 mutant revealed the highest decrease (~2500 fold) in IL1B gene expression among
the point mutants. The PEST domain serine mutation showed an approximately 2-fold lower
mRNA expression than the TAD domain mutations. Once again, there was no significant IL1B
mRNA detected in D1-100 and D8-29 deletions (negative controls) over the background. These
mRNA results agree with the luciferase reporter studies in that these point mutations have an effect
on the Spi1 activation event and IL1B gene transcription in TLR4-activated monocytes. Since
previous studies have demonstrated that Spi1 through its amino-terminal transactivation domain
can recruit TBP (Adamik et al., 2013; Hagemeier et al., 1993), it would be interesting to test the
ability of these Spi1 serine mutants to recruit TBP and Pol II to the IL1B gene promoter relative to
the wild type Spi1 in an HEK293T system using ChIP analysis.

Figure 32. Phosphorylation of serine residues on Spi1 likely plays an important role in IL1B
gene expression. (A) Shows the schematic of wild-type Spi1 with various domains and previously
reported putative serine phosphorylation sites (Celada et al., 1996). The Spi1 schematic is courtesy
of Dr. Philip E Auron. (B) The luciferase assay results for Spi1 point mutants and deletion vectors
as compared to Wild-type Spi1 transfected into HEK293T cells. (C) Relative IL1B mRNA
expression in HEK293T cells transfected with Spi1 point mutants and deletion vectors. Error bars
in panels B and C represent two biological replicates.
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4.4. MATERIALS AND METHODS
4.4.1. Cell Culture, Reagents and Treatment conditions
Cell lines were obtained from American Type Culture Collection (ATCC). THP-1 cells
were cultured in RPMI media (10-040-CV, Cellgro) supplemented with 10% heat-inactivated fetal
bovine serum (SH30070.03, Hyclone), 1% Penicillin/Streptomycin Solution (30-002-CI, Cellgro)
and 500 μl of 2-mercaptoethanol (21985-023, Invitrogen). HEK293T cells were grown in EMEM
(10-010-CV, Cellgro) containing 10% heat-inactivated fetal bovine serum (SH30070.03, Hyclone)
and 1% Penicillin/Streptomycin Solution (30-002-CI, Cellgro). For mRNA and ChIP studies,
THP-1 cells were stimulated with 1µg/ml of E.coli 055:B5 Lipopolysaccharide (LPS) (L2880,
Sigma-Aldrich) and/or with 30ng/ml of Phorbol 12-Myristate 13-Acetate (PMA) (Sigma) for
indicated time periods. For transcription factor inhibitor mRNA studies, the THP-1 cells were
pre-treated with specified inhibitor one hour prior to LPS stimulation. 10 µM of IKK inhibitor III
(BMS-345541, Calbiochem) was used as an NF-κB inhibitor and 10 µM of U0126 (V1121,
Promega) was used as an C/EBPβ inhibitor. For LPS re-stimulation experiments, THP-1 cells were
first treated with 1µg/ml of LPS for 24 hours and then re-stimulated with 1µg/ml of LPS with or
without washing with serum-free RPMI media for indicated time periods. For extracellular
succinate treatment experiments, sodium succinate dibasic hexahydrate (S9637, Sigma) was used
at the indicated concentration.

4.4.2. Transfection constructs
Wild-type TRAF6 vector has been described previously (Wang et al., 2010). Luciferase
reporter XT-Luc IL1B and wild-type IRF8 were as described (Unlu et al., 2007). Expression
vectors containing full-length and Spi1 mutant constructs (D8-29, DPEST (D112-166), Serine to
Alanine substitutions: S41A, S45A, S41A S45A, S148A) were a gift from Richard Maki (The
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Scripps Research Institute, La Jolla, California). The plasmid expressing the D1-100 Spi1were
constructed as described (Kominato et al., 1995)

4.4.3. Cell transfection
HEK293T cells were seeded into either 6-well plates (mRNA studies) or 24-well plates
(luciferase reporter assays) to 60-70% confluency. Expression plasmids were transfection into
HEK293T cells with FUGENE 6 transfection reagent (11814443001, Roche) in a ratio of 3:1 (3
µl of reagent per 1 µg if DNA), according to the manufacturer’s instructions. For luciferase
reporter assays, expression vectors were transfected into HEK293T cells in 24-well plates as
follows: 50 ng of Spi1 wild-type or mutants and 100 ng of wild-type TRAF6, wild-type IRF-8 and
XT-Luc IL1B reporter vector. pECE (empty vector) plasmid was used to maintain a constant
amount of total transfected DNA into each sample. For endogenous IL1B mRNA expression
studies, the expression vectors were transfected into HEK293T cells in 6-well plates as follows:
150 ng of Spi1 wild-type or mutants and 300 ng of wild-type TRAF6 and wild-type IRF-8.

4.4.4. Luciferase Reporter Assays
The luciferase assay system (Promega, E-1501) was used for luciferase reporter assays.
After 24 hours of transfection, cells were then lysed with 60 µl of cell lysis buffer (Promega) in
each well of the 24-well plates and continuously shaken for 20 minutes at room temperature. 20
µl of cell lysate from each well was used to determine the luciferase activity using VERITAS
microplate luminometer (Turner Biosystems, Sunnyvale, CA) according to the manufacturer’s
protocol.
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4.4.5. mRNA Expression Analysis
1x106 THP-1 cells in RPMI-1640 media were plated into 6-well plates (Thermo Fisher
BioLite, 130184). Following treatments, cells were pelleted and the supernatant was removed. The
cell pellet was re-suspended in 500 μl of TRIzol reagent (Invitrogen, 15596026). For endogenous
IL1B mRNA expression studies, HEK293T cells were plated into 6-well plates (Thermo Fisher
BioLite, 130184) and transfected as indicated at 60-70% cell confluency. The RNA was isolated
and converted into cDNA as previously described (Pulugulla et al., 2018a; Pulugulla et al., 2018b).
cDNA was then analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus Applied
Biosystems Real Time Instrument (Thermo Fisher, 4376600). Relative expression levels were
calculated using the DDCt method with GAPDH (Reference gene) and unstimulated THP-1 cells
as a control. Primer Sequences used for mRNA analysis are indicated in Table 6.
Gene

Forward Primer

Reverse Primer

IL1B

TCCAGGGACAGGATATGGAG

TCTTTCAACACGCAGGACAG

TNF

CGTCTCCTACCAGACCAAGG

GGAAGACCCCTCCCAGATAG

GAPDH

ACACCCACTCCTCCACCTTT

CCCTGTTGCTGTAGCCAAAT

Table 6. Primer sequences for mRNA expression analysis. The table shows the forward and
reverse primer sequences used for mRNA analysis.
4.5.6. Chromatin Immuno-precipitation
ChIP was performed using a modification of the Millipore/Upstate protocol
(MCPROTO407). Following treatments, a total of 1x107 THP-1 monocytes in RPMI-1640 media
were fixed in 1% formaldehyde (Fisher, F79-500) for 10 min at room temperature. ChIP and DNA
isolation were performed as previously described (Pulugulla et al., 2018a; Pulugulla et al., 2018b).
Primer Sequences used for ChIP analysis are indicated in Table 7. The size of the PCR products
ranges between 80 and 150 bp. 20 μl qPCR reactions containing 2x Maxima SYBR Green/ROX
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qPCR Master Mix (Thermo Scientific, K0223), 250 nM of primers, and 3 µl of precipitated DNA
were set up in Fast 96-Well Reaction Plates (Applied Biosystems, 4346907). qPCR reactions were
carried out in a StepOnePlus Applied Biosystems Real Time Instrument (Thermo Fisher, 4376600).
Fold enrichment was calculated based on Ct as 2(DCt), where DCt = (CtInput - CtIP). Final enrichment
values were adjusted by subtraction of the nonspecific IgG antibody binding.
Position

Forward Primer

Reverse Primer

-2790 IL1B

ATAGCACAGTGTGGTTGAAGCAG
C
CCTGACAATCGTTGTGCAGTTGA
TG
GAGTATTGGTGGAAGCTTCTTAG
GG
GCAGAAGTAGGAGGCTGAGAAA

+4858 IL1B

ACATGGCAGAACTGTGGAGACT
GT
TGTGTGTCTTCCACTTTGTCCCA
C
TTGCTACTCCTTGCCCTTCCATG
A
CCCTAAGAAGCTTCCACCAATA
CTC
AGTAGCCAAAGCCTCTGCAC

-600 TNF

AATCAGGGACCCCAGAGTTC

GGAATTCACAGACCCCACTG

-128 TNF

GGAGAAGAAACCGAGACAGAA
GGT
ATGTGTCTTGGAACTTGGAGGG
CT

CTTCCTTGGTGGAGAAACCCATG
A
TATCCCACTAAGGCCTGTGCTGT
T

-279 IL1B
-155 IL1B
-91 IL1B

+1326 TNF

CCGATTCCAAAGAAACAGGA

Table 7. Human IL1B and TNF ChIP primer sequences. Primer sequences used for ChIP
analysis.

96

Chapter 5: Conclusion and Future Directions
This dissertation focuses on the examination of various molecular mechanisms that
regulate IL1B gene expression. The first major finding highlighted in chapter 2 focused on
understanding IL1B gene expression and its chromatin status in human tonsillar CD4 T cells. Our
mRNA expression studies demonstrate that TCR-activation of CD4 T cells results in IL1B gene
expression in these cells. Interestingly, the IL1B gene in TCR-activated CD4 T cells is
slowly-induced with maximal expression after 72 hours, contrasting that of TLR4-activated
monocytes, where the IL1B gene is expressed both at much higher levels (~1000-fold greater) and
with rapid maximal gene expression within the first 3-4 hours. In order to explore whether distinct
mechanisms regulate IL1B gene expression in CD4 T cells and monocytes, we examined the
epigenetic status of IL1B in TCR-activated CD4 T cells, showing that, in contrast to monocytes,
the IL1B gene in CD4 T cells is expressed from a low-activity bivalent promoter containing both
active H3K4me3 and repressive H3K27me3 gene expression nucleosome marks.
In monocytes, Spi1 is known to broadly act as a “pioneer factor” possessing the ability to
associate with nucleosomal DNA and either physically remodel or displace nucleosomes (Barozzi
et al., 2014; Calo and Wysocka, 2013; Iwafuchi-Doi et al., 2016), and likely also opens chromatin
that our laboratory has reported for the IL1B promoter (Adamik et al., 2013). We have reported
that Spi1, which is absolutely necessary for IL1B gene expression in monocytes and macrophages,
is absent in TCR-activated CD4 T cells. A nucleosome is present at the Spi1 binding site of the
IL1B promoter in unstimulated and TCR-activated CD4 T cells, supporting the argument that IL1B
gene expression in CD4 T cells is independent of Spi1. The absence of Spi1 might be one of the
reasons for the low-level induction of IL1B in CD4 T cells in comparison to TLR4-activated
monocytes. For future studies, it would be informative to ectopically express Spi1 in CD4 T cells
prior to TCR-activation to determine whether the presence of Spi1 in these cells results in an
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increased and immediate-early IL1B gene induction, similar to that of monocytes. In order to
evaluate whether Spi1 is generally capable of inducing IL1B transcription in other T cells, similar
studies could also be conducted in either A3.01 or Jurkat T cell line. Chromatin
Immunoprecipitation could be used to determine whether ectopically expressed Spi1, functioning
as a pioneer factor, can displace the single nucleosome that we reported to be blocking the Spi1
binding site on the IL1B promoter in CD4 T cells (Pulugulla et al., 2018a). Moreover, the
transcription factors responsible for IL1B gene induction in CD4 T cells after TCR-activation is
unknown. Previous studies have shown that TCR-activation can induce NF-κB activity
(Coudronniere et al., 2000; Thaker et al., 2015; Wang et al., 2004), which is known to be important
in IL1B gene expression in monocytes (Adamik et al., 2013). Using relatively specific transcription
factor inhibitors and ChIP studies, it should be able to be determined whether NF-κB plays a role
in IL1B gene induction in CD4 T cells, similar to that which it plays in TLR-4 activated monocytes.
Other than NF-κB, transcription factors like IRF-4 (Klein et al., 2015; Zhang et al., 2008), IRF-8
(Unlu et al., 2007), AP-1 (Roman et al., 2000) and C/EBPβ (Adamik et al., 2013) that are known
to be important for IL1B gene expression in monocytes can also be evaluated in TCR-activated
CD4 T cells.
The third chapter of this dissertation focuses on understanding the molecular structure of a
critical long-range protein-protein interaction between Spi1 and C/EBPβ at the IL1B promoter and
its upstream enhancer using a combination of computational and experimental approaches. We
have reported the predicted structure of the Spi1:C/EBPβ interaction on the IL1B promoter using
computational docking and molecular dynamic simulations. These computational and in vitro
approaches revealed that the C-terminal Cysteine (Cys-345) of C/EBPβ is involved in a strong
critical salt-bridge with Arg-232 located within the DNA-recognition helix of Spi1. A pocket
surrounding Arg-232 was computationally screened in order to identify small molecules that might
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disrupt the Spi1:C/EBPβ interaction. L-Arginine was one of the highest-scoring small molecules
that could bind into the pocket surrounding Arg-232 of Spi1 in LPS-activated THP-1 cells. We
discovered that soluble L-Arginine added to the media significantly reduced IL1B gene expression
and the interaction of C/EBPβ with Spi1 on the IL1B promoter in TLR4-activated monocytes.
These results, along with our laboratory’s previous mutation studies (Listman et al., 2005) suggest
that the Spi1:C/EBPβ interaction on the IL1B promoter plays an important role in IL1B gene
transcription and can be potentially targeted using small molecule inhibitors. This is also the first
example that we are aware of a specific druggable promoter, possibly related to the unique
involvement of Spi1, a specific transcription activator, acting at the IL1B promoter as a general
transcription factor (i.e., a factor similar to those of TBP and the RNA Polymerase II pre-initiation
complex that are associated with the general process of transcription). IL-1β protein plays a central
role in many anti-inflammatory diseases and current anti-IL-1β therapies target the “storm” of
IL-1β protein molecules downstream of IL1B gene transcription. However, this study provides an
unique approach to target IL-1β at the transcription level and act as a model to design novel
anti-inflammatory small molecules that can potentially target IL1B gene induction. This approach
can be expanded by testing other small molecules from the computational screen with high
potential to both enter the cell and bind to the Spi1:C/EBPβ interaction pocket. Molecules that
have the potential to decrease IL1B gene transcription by disrupting the Spi1:C/EBPβ interaction
at the IL1B gene promoter, without affecting the direct interaction of either Spi1 or C/EBPβ with
DNA can be further evaluated. We were fortunate in our use of L-Arginine because it can be taken
up by macrophages like THP-1 cells at reasonable concentrations. However, other potential
inhibitors that might be effective direct inhibitors may not be readily transported into cells. Since
the primary target is inside the cell, a direct means of evaluation of compounds for inhibiting the
Spi1:C/EBPβ interaction is critical, with methods of intracellular transport being an important, but
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secondary goal. One of the potential techniques for ex vivo testing of compounds would be to use
glutathione-s-transferase fusions, as we have reported (Pulugulla et al., 2018b). However, even
more effective and with a broader set of capabilities, a technique like surface plasmon resonance
might be most effective in characterizing a small molecule’s binding kinetics, concentration and
affinity (Huber and Mueller, 2006). This sensitive and quantitative approach extensively used in
drug discovery can be utilized to rapidly screen binding on and off rates for numerous compounds
under various conditions, generating structural characteristics for binding that can be readily
evaluated for cell uptake. Selected compounds from this screen can then be derivatization, if
required, in preparation for pre-clinical animal trials involving organism cytotoxicity,
pharmacokinetics and dynamics prior to testing for efficacy in in vivo diseased animal models.
The fourth chapter contains a series of unpublished preliminary results that provide new
molecular insights into IL1B gene regulation. Using mRNA expression and ChIP, we have
demonstrated a differential functional role for NF-κB and C/EBPβ in IL1B and TNF gene
expression for LPS and PMA-activated THP-1 cells. Our results suggest that NF-κB is required
for both early and late expression of the IL1B gene in LPS-activated monocytes. Recent studies
have revealed that the TLR-4 receptor gets internalized and activates NF-κB in a secondary kinetic
late phase via TRIF adaptor function (Cheng et al., 2015; Tan et al., 2015; Zanoni et al., 2011).
This raises the question as to whether the TRIF pathway plays a role in the sustained late phase
expression of the IL1B gene that might be resolved by using available TRIF inhibitors. We have
preliminary evidence that extracellular succinate may support LPS re-stimulation of the IL1B gene
in THP-1 monocytes as a form of Trained Innate Immune Memory (Netea et al., 2016; Quintin et
al., 2014). Finally, we have demonstrated that TLR4-dependent phosphorylation of Spi1 plays an
important role in IL1B gene transcription. As hypothesized in Chapter 4, this study can be further
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expanded to determine whether Spi1 phosphorylation is necessary for TBP recruitment to the IL1B
gene promoter.
The work highlighted in this dissertation provides new molecular insights into IL1B gene
expression in monocytes and lymphoid CD4 T cells. Results from this work could be used to
design future studies that would assist in discovering potential regulatory control points for this
immunologically important gene, which could ultimately lead to the development of novel
antiIL-1β therapeutics.
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APPENDICES
APPENDIX A1

A

B

Appendix A1. CD4 T cells express proIL-1β following TCR stimulation independent of Spi1.
(1) Full-length blots of cropped images from Fig. 1C. The short and long exposures of proIL-1β
and Spi1 blots illustrate the relative abundance of these proteins in ex vivo TCR-activated CD4 T
cells in comparison with resting CD4 T cells, HEK293 cells, and THP-1 cells (unstimulated or
LPS-treated for 1.5 h) for two individual patient donors. Membranes were stripped and re-probed
for β-actin. Samples were normalized by cell equivalents, 1.5x105 for all lanes. (2) Full-length
blots of cropped images from Fig. 2D show expression of proIL-1β for in vivo-differentiated
CCR5+ and naïve CCR5- CD4 T lymphocytes from two individual patient donors. HEK293,
unstimulated and 1.5 h LPS-treated THP-1 cells were used as controls. Membranes were stripped
and re-probed for β-actin. Samples were normalized by cell equivalents: 1.5x104 cell equivalents
for THP-1+LPS and 1.5x105 in all other lanes.
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